| T |
|
T1-WEIGHTED MAGNETIC RESONANCE IMAGING DIFFERENTIATES PLATELETS IN PULMONARY EMBOLI EX VIVO
|
| Tratar G., Blinc A., Podbregar M., Kralj E., Balazic J., Sabovic M., Sersa I. |
| |
|
TACHYKININS AND THE NEUROKININ RECEPTOR 1 ARE REQUIRED FOR PLATELET THROMBUS FORMATION
|
| Jones S., Tucker K.L., Sage T., Barrett N.E., Lowry P.J., Zimmer A., Hunt S.P., Gibbins J.M. |
| |
|
TAFI ACTIVATION IN MODEL THROMBI
|
| Lisiak K.M., Booth N.A. |
| |
|
TAFI ACTIVITY LEVELS AND RECURRENT VENOUS THROMBOEMBOLIC DISEASE
|
| Bulabois B., Marlu R., Barro C., Pernod G., Pouzol P., Polack B. |
| |
|
TALIN HEAD-ROD INTERACTION MODULATES INTEGRIN BINDING TO THE TALIN HEAD DOMAIN
|
| Xing B., Yu J., Li J., Zeng L., Chishti A.H., Du X., Lam S.C.T. |
| |
|
TANDEM MEASUREMENT OF D DIMER AND MYELOPEROXIDASE DECREASES UNNECESSARY PULMONARY VASCULAR IMAGING IN EMERGENCY DEPARTMENT PATIENTS EVALUATED FOR PULMONARY EMBOLISM
|
| Nordenholz K.E., Mitchell A.M., Kline J.A. |
| |
|
TARGETED INHIBITION OF THE SEROTONIN 5-HT2A RECEPTOR ATTENUATES RECURRENT PLATELET-MEDIATED THROMBOSIS IN AN IN VIVO MODEL MIMICKING UNSTABLE ANGINA
|
| Przyklenk K., Linden M.D., Frelinger III A.L., Michelson A.D. |
| |
|
TEN NOVEL MUTATIONS IN FXI GENE
|
| Castaman G., Giacomelli S.H., Ghiotto R., Tagliaferri A., Habart D., Dragani A., Tosetto A., Duga S., Rodeghiero F. |
| |
|
TEN YEARS FOLLOW UP OF HEREDITARY HAEMORRHAGIC PARIENTS IN DENTAL PRACTICE
|
| Makris P.E., Makris S.P., Makris M.P. |
| |
|
TENSILE STRENGTH OF THE NATIVE BLOOD CLOTS
|
| Savushkin A.V. |
| |
|
TEST OF ASPIRIN RESISTANCE
|
| Kristensen S.R., Madsen E.H., Gehr N., Johannesen N.L., Schmidt E.B., Poulsen T.S. |
| |
|
TESTING AGONIST-INDUCED PLATELET AGGREGATION BY THE IMPACT-R
|
| Shenkman B., Einav Y., Salomon O., Varon D., Savion N. |
| |
|
TESTING FVIIA EFFICACY AS A POTENTIAL TREATMENT FOR PATIENTS WITH HERMANSKY-PUDLAK-SYNDROME TYPE 1 (HPS-1) WITH A THROMBIN GENERATION TEST (TGT) IN TWO CASES
|
| Wegert W., Mondorf W., Scholz T., Kirchmaier C.M. |
| |
|
TESTOSTERONE INDUCES PHOSPHORYLATION OF P38 AND JNK IN HUVEC
|
| Powazniak Y., Kempfer A.C., Farías C., Keller L., Dominguez M.P., Calderazzo J.C., Lazzari M.A. |
| |
|
TETRASPANIN CD9 MODULATES VASCULAR SMOOTH MUSCLE CELL MIGRATION AND PROLIFERATION IN VITRO AND NEOINTIMA FORMATION IN VIVO
|
| Prakash K.J., Zhang C., Longhurst C.M., Lu Y., Jacobs J., Jennings L.K. |
| |
|
TF EXPRESSION IN HUMAN PLACENTA IS SIGNIFICANTLY ASSOCIATED WITH VEGF EXPRESSION
|
| Chinni E., Colaizzo D., Margaglione M., Rubini C., Di Vagno G., Giuliani F., Grandone E. |
| |
|
TFPI LEVELS AND HAEMORRHAGIC EVENTS IN HAEMOPHILIC PATIENTS
|
| Tardy-Poncet B., Reynaud J., Piot M., Campos L. |
| |
|
TFPI PLASMA LEVELS IN WOMEN WITH PRE-ECLAMPSIA
|
| Dusse L.M.S., Carvalho M.G., Cooper A.J., Lwaleed B.A. |
| |
|
TGFBETA1 IS RESPONSIBLE FOR HIGH-GLUCOSE-INDUCED ENRICHMENT OF PERICELLULAR MATRIX WITH HYALURONIC ACID. DIFFERENT MECHANISMS FOR ENDOTHELIAL AND MESANGIAL CELLS
|
| Yevdokimova N., Komisarenko S. |
| |
|
THALIDOMIDE AND THROMBOPROPHYLAXIS: TO WHOM AND WHEN
|
| Callejas M., García-Raso A., Román A., Prieto E., Soto C., Lopez Lorenzo J.L., Paniagua C., Llamas P. |
| |
|
THE 3'UTR PROTHROMBIN GENE POLYMORPHISMS IN THROMBOHILIC SERBIAN POPULATION
|
| Djordjevic V., Nestorovic A., Tomic B., Miljic P., Mikovic D., Kovac M., Antonijevic N., Rakicevic L., Radojkovic D. |
| |
|
THE 4G/5G INSERTION/DELETION POLYMORPHISM OF THE PLASMINOGEN ACTIVATOR INHIBITOR-1 GENE IS ASSOCIATED WITH VENOUS THROMBOSIS
|
| Saour J., Sheereen A., Mammo L. |
| |
|
THE A/T1381 POLYMORPHISM IN THE A1-DOMAIN OF VON WILLEBRAND FACTOR INFLUENCES THE AFFINITY OF VON WILLEBRAND FACTOR FOR PLATELET GLYCOPROTEIN IB-ALPHA
|
| Szanto T., Schlammadinger A., Staelens S., De Meyer S.F., Freson K., Pareyn I., Vauterin S., Harsfalvi J., Deckmyn H., Vanhoorelbeke K. |
| |
|
THE ABCB1 (MDR1) C3435T POLYMORPHISM DOES NOT INFLUENCE PHARMACODYNAMIC RESPONSE TO CLOPIDOGREL IN HEALTHY SUBJECTS
|
| Hulot J.S., Villard E., Azizi M., Vrignaud C., Remones V., Aiach M., Lechat P., Gaussem P. |
| |
|
THE ABILITY OF TF TO PROMOTE TUMOUR CELL IMMUNE EVASION, MEDIATED VIA SURFACE VCAM-1
|
| Li C., Collier M.E.W., Frentzou A., Ettelaie C. |
| |
|
THE ABSOLUTE RISK OF VENOUS THROMBOSIS AFTER AIR TRAVEL: EFFECT OF RISK FACTORS AND BEHAVIOUR DURING FLIGHTS
|
| Kuipers S., Cannegieter S.C., Middeldorp S., Büller H.R., Rosendaal F.R. |
| |
|
THE ADDITIVE ANTIPLATELET ACTION OF CLOPIDOGREL IN PATIENTS WITH CORONARY ARTERY DISEASE TREATED WITH ASPIRIN
|
| Dropinski J., Jakiela B., Sanak M., Wegrzyn W., Biernat M., Dziedzina S., Plutecka H., Szczeklik A. |
| |
|
THE ALPHA FIBRINOGEN THR312ALA POLYMORPHISM AND VENOUS THROMBOEMBOLISM IN AMERICAN CAUCASIANS AND AFRICAN AMERICANS: THE GATE STUDY
|
| Lally C., Hooper C., Austin H., Pyle M., Ellingsen D., Kulkarni R. |
| |
|
THE ANALYSIS OF TREATMENT BY rFVIIa IN CARDIO SURGICAL BLEEDING
|
| Hulikova M. |
| |
|
THE ANTI-COAGULANT AND THE ANTI-THROMBOTIC EFFECT OF MCC-977, A NOVEL ORALLY-ACTIVE THROMBIN INHIBITOR
|
| Nakajima M., Suga M., Sugawara K., Yamada K., Anabuki J., Yamamoto T., Kitada Y. |
| |
|
THE ANTICOAGULANT PROTEINS S AND ANTITHROMBIN DISPLAY REMARKABLE SEX-DEPENDENT CHANGES DURING AGING
|
| Gehrisch S., Böttcher A., Kuhlisch E., Schwarz T., Schellong S., Siegert G. |
| |
|
THE ANTITHROMBIN III SERINE-380 P14 HYDROXYL MAKES CRITICAL CONTRIBUTIONS TO METASTABILITY OF THE NATIVE CONFORMATION AND TO STABILIZATION OF THE HEPARIN-BOUND ACTIVATED STATE
|
| Jairajpuri M.A., Luis S.A., Lu A., Olson S.T., Huntington J.A., Bock S.C. |
| |
|
THE ANTITHROMBOTIC EFFECT OF AR-H067637, THE ACTIVE FORM OF THE NOVEL ORAL DIRECT THROMBIN INHIBITOR AZD0837, IN RAT MODELS OF ARTERIAL AND VENOUS THROMBOSIS
|
| Pehrsson S., Elg M. |
| |
|
THE ASSOCIATION OF DEPRESSION WITH PLATELET ACTIVATION: EVIDENCE FOR A TREATMENT EFFECT
|
| Morel-Kopp M.C., Chen Q., McLean L., Tennant C.C., Tofler G.H., Ward C.M. |
| |
|
THE AUTOMATED ENDOGENOUS THROMBIN POTENTIAL (ETP) TEST TO REFLECT COAGULATION CHANGES IN PATIENTS WITH CIRRHOSIS OF THE LIVER
|
| Gadisseur A.P., Schouten J., Francque S., Vangenechten I., Vertessen F., Michielsen P., Van der Planken M.G. |
| |
|
THE BIOCHEMICAL IMPORTANCE OF GLYCOSYLATION IN THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR
|
| Buelens K., Hillmayer K., Declerck P.J., Gils A. |
| |
|
THE BIPHASIC APTT WAVEFORM AS A BIOMARKER FOR TARGETING TREATMENT WITH RECOMBINANT ACTIVATED PROTEIN C (APC)
|
| Dutt T., Powell C., Downey C., Toh C.H. |
| |
|
THE CANADIAN RARE INHERITED BLEEDING DISORDERS REGISTRY (RIBDR) OF COAGULATION FACTOR DEFICIENCIES AND PLATELET FUNCTION DISORDERS
|
| Rand M.L., Clark D., Walker I., Wu J. |
| |
|
THE CAPACITY TO GENERATE THROMBIN IN FACTOR VIII INHIBITOR PLASMAS DIFFERS AMONG COMMERCIAL CONCENTRATES AND IS ASSOCIATED WITH VON WILLEBRAND FACTOR CONTENT. IS THIS OF IMPORTANCE FOR ITI SUCCESS?
|
| Berntorp E., Ekman M., Astermark J. |
| |
|
THE CARRIAGE OF FV G1691A, FII G20210A, MTHFR C677T GENES IN PATIENTS WITH ISCHEMIC STROKE IN BURYATS AND RUSSIANS
|
| Vitkovsky Y.A., Strambovskaya N.N., Gergesova E.E. |
| |
|
THE CENTRAL LINKER OF CALCIUM- AND INTEGRIN-BINDING PROTEIN 1 FUNCTIONS AS A TETHER AND IS CRITICAL FOR BINDING THE CYTOPLASMIC TAIL OF THE INTEGRIN ALPHA IIB SUBUNIT
|
| Blamey C.J., Bahnson B.J., Naik U.P. |
| |
|
THE CENTRAL ROLE OF THROMBIN IN HAEMOSTASIS
|
| Crawley J.T.B., Zanardelli S., Chan K.N.K., Lane C., Lane D.A. |
| |
|
THE CHALLENGE OF PRAEOPERATIVE INVESTIGATION OF HEREDITARY AND ACQUIRED COAGULATION DISORDERS IN CHILDREN AND ADOLESCENTS
|
| Weidenhammer A., Auerswald G., Bidlingmaier C., Kurnik K., Halimeh S. |
| |
|
THE CHANGE AND MUTUAL RELATIONS BETWEEN PROTEIN Z AND PARTIAL INFLAMMATORY FACTORS IN CEREBRAL INFARCTION
|
| Pan X. |
| |
|
THE CHEMOKINE FRACTALKINE MEDIATES LEUKOCYTE RECRUITMENT TO INFLAMMATORY ENDOTHELIUM AT ARTERIAL SHEAR RATES IN VIVO AND IN VITRO
|
| Schulz C., Schäfer A., Stolla M., von Brühl M.L., Bauersachs J., Massberg S. |
| |
|
THE CHROMOGENIC FVIII:C ASSAY IS A SUITABLE ALTERNATIVE TO THE TWO-STAGE ASSAY IN DETECTION OF MILD HAEMOPHILIA A PATIENTS WITH ONE-STAGE, TWO-STAGE DISCREPANCY
|
| Bowyer A.E., Kitchen S., Makris M. |
| |
|
THE CLINICAL RELEVANCE OF PLATELET HETEROGENEITY AND ACTIVATION IN PATIENT WITH ANTIPHOSPHOLIPID SYNDROME
|
| Vasilenko I., Savushkin A., Reshetnyak T., Bichkova I., Nesterenko I., Zaguzin A. |
| |
|
THE CLINICAL RESULTS OF P32 RADIOSYNOVECTOMY IN HEMOPHILIC PATIENTS WITH CHRONIC SYNOVITIS
|
| Mortazavi S.J., Asadollahi S., Farzan M., Shahriaran S., Aghili M., Izadyar S., Lak M. |
| |
|
THE CLINICAL VALIDATION OF A NEW QUANTITATIVE HIGH SENSITIVE D-DIMER ASSAY
|
| Haas F.J.L.M., Schutgens R.E.G., Biesma D.H. |
| |
|
THE COAGULOPATHY OF MASSIVE TRANSFUSION
|
| Hardy J., Ozier Y. |
| |
|
THE CONSTRUCTION OF A HUMANIZED PHAGE ANTIBODY LIBRARY OF ANTI-PLATELET GPIIB/IIIA SINGLE CHAIN FV
|
| Ji X.B., Ma D.X., Li L.Z., Peng J., Wang L., Hou M. |
| |
|
The contribution of phospholipids (PL) to thrombin generation (TG) induced by factor eight inhibitor bypassing activity (FEIBA) and recombinant factor VIIa (rFVIIa)
|
| Livnat T., Zivelin A., Martinowitz U., Seligson U. |
| |
|
THE COOPERATIVE ACTIVITY OF THE MIDDLE AND DISTAL CARBOXYL TERMINAL DOMAINS OF ADAMTS13 IS CRUCIAL FOR BINDING VON WILLEBRAND FACTOR UNDER FLOW
|
| Zhang P., Pan W., Rux A.H., Sachais B.S., Zheng X. |
| |
|
THE CORRELATION OF SERUM FERRITIN AND PLATELET ACTIVATION IN BETA-THALASSEMIA MAJOR
|
| Ruchutrakool T., Karoopongse E., Nakkinkun Y., Issaragrisil S. |
| |
|
THE COURSE OF D-DIMER AND FACTOR VIII LEVELS DURING THE ACUTE PHASE OF LEG DEEP VENOUS THROMBOSIS AND RELATIONSHIP WITH THE THROMBOTIC BURDEN
|
| Favaretto E., Cosmi B., Legnani C., Cini M., Filippini M., Pili C., Palareti G. |
| |
|
THE CRITICAL ROLE OF MYOSIN IIA IN PLATELET INTERNAL CONTRACTION
|
| Johnson G.J., Leis L.A., Krumwiede M.D., White J.G. |
| |
|
THE DIFFERENCES OF PLATELET RESPONSE TO SNAKE VENOMS: COMPARATIVE STUDY OF CHILDREN AND ADULTS
|
| Kern L., Ignjatovic V., Winkel K., Summerhayes R., Monagle P. |
| |
|
THE DIFFERENT SENSITIVITY OF TWO APTT REAGENTS FOR DIAGNOSIS OF LUPUS ANTICOANGULANT
|
| Buliková A., Zavrelová J., Smejkal P., Penka M. |
| |
|
THE DIFFERENTIAL EFFECTS OF ACIDOSIS ON FIBRINOGEN SYNTHESIS AND DEGRADATION IN PIGS
|
| Martini W.Z., Christensen S., Dubick M.A. |
| |
|
THE DISCRIMINATION OF GENERIC FORMS OF LMW HEPARIN USING A PROTEOMIC BLOOD BASED APPROACH
|
| Goodwin C.A., Scully M.F., Kakkar A.K. |
| |
|
THE DISCRIMINATION OF GENERIC FORMS OF LMW HEPARIN USING A PROTEOMIC CELL-BASED APPROACH
|
| Goodwin C.A., Clutterbuck R., Scully M.F., Kakkar A.K. |
| |
|
THE DISTAL CARBOXYL-TERMINAL DOMAINS OF ADAMTS13 ARE REQUIRED IN VIVO FOR EFFICIENT CLEAVAGE OF VON WILLEBRAND FACTOR UNDER PROTHROMBOTIC CONDITIONS
|
| Banno F., Kokame K., Yang J., Miyata S., Miyata T. |
| |
|
THE DISTRIBUTION OF FACTOR SEVEN ACTIVATING PROTEASE (FSAP) IN CAROTID AND CORONARY ATHEROSCLEROTIC PLAQUES IN SUBJECTS GENOTYPED FOR THE MARBURG I POLYMORPHISM
|
| Parahuleva M.S., Grebe M., Voss R., Parviz B., Barth A., Tillmanns H., Sedding D.G., Hoelschermann H., Kanse S.M. |
| |
|
THE DISTURBED MULTIMER PATTERN OF VWF R1374C IS NOT DUE TO INCREASED ADAMTS13 MEDIATED PROTEOLYSIS
|
| Staelens S., Pareyn I., Feys H.B., Vauterin S., Wijns W., Deckmyn H., Vanhoorelbeke K. |
| |
|
THE DUAL ROLE OF INTRINSIC GENERATED PLASMIN IN THE REGULATION OF THE HEMOSTATIC BALANCE
|
| van Heerde W.L., Lap P., Janssen J., Loof A.H., Novakova I.R.O., Verbruggen B.W., Boezeman J., van Kraaij M.G.J. |
| |
|
THE DYNAMICS OF THE BINDING OF PLASMINOGEN AND TPA TO IMMOBILIZED HIGH MOLECULAR WEIGHT FIBRIN DEGRADATION PRODUCTS
|
| Cook P., Munro K.A., Nesheim M.E. |
| |
|
THE EFFECT OF ABO BLOOD GROUP ON VON WILLEBRAND FACTOR PROPEPTIDE LEVELS IN NORMAL INDIVIDUALS
|
| Haberichter S.L., Morateck P., Perry C., Christopherson P., Hoffman R.G., Gill J.C., Montgomery R.R. |
| |
|
THE EFFECT OF ACTIVATED FACTOR IX ON THE FACTOR IX COAGULANT AND NAPTT ACTIVITY OF A HIGH-PURITY FACTOR IX CONCENTRATE
|
| Pickering W.M., Gray E. |
| |
|
THE EFFECT OF ADP RECEPTOR ANTAGONISTS AND ASPIRIN ON WHOLE BLOOD PLATELET AGGREGATION MEASURED BY MULTIPLE ELECTRODE AGGREGOMETRY
|
| Toth O., Penz S., Calatzis A., Losonczy H., Siess W. |
| |
|
THE EFFECT OF AGE AND GENDER ON THE PHARMACOLOGY AND SAFETY OF THE ORAL, DIRECT FACTOR XA INHIBITOR RIVAROXABAN
|
| Kubitza D., Becka M., Mueck W., Zuehlsdorf M. |
| |
|
THE EFFECT OF ANTICOAGULANTS ON CANCER RISK AND SURVIVAL: SYSTEMATIC REVIEW
|
| Tagalakis V., Robinson-Cohen C., Blostein M., Kahn S.R. |
| |
|
THE EFFECT OF APCC AND PCC ON THE GENERATION OF THROMBIN IN HAEMOPHILIA A PATIENTS WITH FVIII INHIBITOR: A CROSS-OVER PHARMACOKINETIC STUDY
|
| Windyga J., Varadi K., Baran B., Keil B., Turecek P. |
| |
|
THE EFFECT OF APHERESIS ON DONORS' PLATELETS
|
| Garner S.F., Jones C.I., Walton J., Angenent W., Bernard A., Burns P., Dudbridge F., Rankin A., Stephens J., Tom B.D., Ouwhand W.H., Goodall A.H. |
| |
|
THE EFFECT OF BIBT 986, A NOVEL SMALL MOLECULE DUAL INHIBITOR OF THROMBIN AND FACTOR XA, ON COAGULATION IN A MODEL OF ENDOTOXIN INDUCED, TISSUE FACTOR TRIGGERED COAGULATION ACTIVATION IN HUMANS
|
| Leitner J.M., Jilma B., Mayr F.B., Cardona F., Spiel A.O., Firbas C., Rathgen K., Graefe-Mody E.U., Staehle H., Schuehly U. |
| |
|
THE EFFECT OF DIRECT THROMBIN INHIBITORS (DTIS) IN CLOTTING PLASMA
|
| Wagenvoord R.J., Deinum J., Elg M., Hemker C. |
| |
|
THE EFFECT OF EXERCISE ON FIBRINOLYTIC AND COAGULATION SYSTEMS IN HEALTHY VOLUNTEERS
|
| Kahraman S., Demirkan F., Bediz C., Alacacioglu I., Aksu I., Piskin O., Turgut N., Ozcan M., Ozsan H., Undar B. |
| |
|
THE EFFECT OF EXERCISE ON INDIVIDUALS WITH TYPE 1 AND TYPE 2B VON WILLEBRAND DISEASE (VWD)
|
| Stakiw J., Bowman M., Hegadorn C., Pruss C., Notley C., Groot E., Lenting P., Lillicrap D., James P. |
| |
|
THE EFFECT OF FIBRINOGEN GLYCATION ON FIBRIN NETWORK STRUCTURE OF TYPE II DIABETIC SUBJECTS
|
| Pieters M., Pieters M., Covic N., Van der Westhuizen F.H., Nagaswami C., Baras Y., Loots D., Jerling J.C., Weisel J.W. |
| |
|
THE EFFECT OF FLIGHT-RELATED BEHAVIOUR ON THE RISK OF VENOUS THROMBOSIS AFTER AIR TRAVEL
|
| Schreijer A.J.M., Cannegieter S.C., Doggen C.J.M., Rosendaal F.R. |
| |
|
THE EFFECT OF HIRUDIN ON THROMBIN GENERATION, APTT AND ECARIN CLOTTING TIME (ECT)
|
| Carlo A., Van Dreden P., Samama M.M., Woodhams B.J. |
| |
|
THE EFFECT OF INTRANASAL DESMOPRESSIN VS. ORAL TRANEXAMIC ACID ON MENSTRUAL BLOOD LOSS AMONG WOMEN WITH MENORRHAGIA AND ABNORMAL LABORATORY HEMOSTASIS: A MULTICENTER, RANDOMIZED CROSS-OVER STUDY
|
| Kouides P.A., Heit J.A., Philipp C.S., Stein S.F., Lukes A.S., Skerrette N.I., Byams V.R., Dowling N.F., Miller C.H., Kulkarni R. |
| |
|
THE EFFECT OF TEST CONDITIONS ON THROMBOELASTOGRAPHY PARAMETERS IN HEMOPHILIACS WITH AND WITHOUT INHIBITORS
|
| Young G., Yassin D., Nugent D.J. |
| |
|
THE EFFECT OF THE INTRONIC PROTHROMBIN 19911G ALLELE ON 3' END MRNA PROCESSING IN RELATION TO THE 20210GA POLYMORPHISM
|
| van der Putten H.H.A.G., Spaargaren-van Riel C.C., Bertina R.M., Vos H.L. |
| |
|
THE EFFECT OF THE SUGARBAKER PROCEDURE ON HAEMOSTASIS
|
| Leversuch W.K., Needham J., Roy A., Milne A., Moran B., Knight G. |
| |
|
THE EFFECTS OF BLOCKING P2Y12 RECEPTOR IN ARTEROSCLEROSIS PRODUCED BY MURINE ALLO-TRANSPALANTATION
|
| Yashiro K., Matsumoto Y., Suzuki Y., Kondo K., Umemura K. |
| |
|
THE EFFECTS OF DOCOSAHEXAENOIC ACID IN PLATELETS (AN EX VIVO STUDY) AND IN MEGAKARYOCYTIC CELLS (AN IN VITRO STUDY)
|
| Guillot N., Carreras M., Laville M., Lagarde M., Vericel E. |
| |
|
THE EFFICACY AND SAFETY OF ANTITHROMBIN CONCENTRATE IN CHILDREN RECEIVING HEPARIN INFUSIONS
|
| Traivaree C., Brandao L., Kahr W., Lau W., Chan A., Williams S. |
| |
|
THE EFFICACY AND SAFETY OF FRESH FROZEN PLASMA (FFP) AND SYSTEMIC TISSUE PLASMINOGEN ACTIVATOR FOR TREATMENT OF INTRAVASCULAR THROMBOSIS IN INFANTS
|
| Traivaree C., Brandao L., Chan A., Williams S. |
| |
|
THE ENDOGENOUS THROMBIN POTENTIAL AND THE RISK OF VENOUS THROMBOEMBOLISM
|
| Chantarangkul V., Tripodi A., Martinelli I., Battaglioli T., Clerici M., Mannucci P.M. |
| |
|
THE EXPRESSION OF PLATELET RECEPTORS AND MARKERS OF PLATELET ACTIVATION IN PATIENTS WITH HEMOPHILIA A AND VON WILLEBRANDS DISEASE
|
| Holmström M., Schulman S., Soutari N., Egberg N., Sten-Linder M. |
| |
|
THE F11 RECEPTOR (F11R, JAM-A) IN ATHEROTHROMBOSIS: OVEREXPRESSION OF F11R IN ATHEROSCLEROTIC PLAQUES
|
| Babinska A., Azari B.M., Salifu M.O., Liu R., Jiang X.C., Sobocka M.B., Boo D., Khoury G., Deitch J.S., Marmur J.D., Ehrlich Y.H., Kornecki E. |
| |
|
THE FACTOR II G20210A VARIANT, POOR PATENCY RATES, AND OLDER AGE AT ONSET ARE INDEPENDENT RISK FACTORS FOR RECURRENT VENOUS THROMBOEMBOLISM
|
| Nowak-Gottl U., Kenet G., Kirkham F.J. |
| |
|
THE FACTOR VII ACTIVATING PROTEASE (FSAP) POLYMORPHISM (G534E) IS ASSOCIATED WITH A DECREASED RISK FOR RESTENOSIS AFTER PERCUTANEOUS CORONARY INTERVENTION
|
| Pons D., Kanse S.M., de Maat M.P.M., Doevendans P.A.F.M., de Winter R.J., Tio R.A., Jukema J.W. |
| |
|
THE FACTOR VIII C1 DOMAIN CONTRIBUTES TO EFFICIENT LRP/LDL RECEPTOR BINDING
|
| Meijer A.B., Limburg V., Meems H., van der Zwaan C., Mertens K. |
| |
|
THE FIRST CAUSATIVE MUTATION OF HAEMOPHILIA A IDENTIFIED IN THE PROMOTER REGION OF THE FACTOR VIII GENE (F8)
|
| Dai L., Cutler J.A., Rangarajan S., Savidge G.F., Mitchell M.J. |
| |
|
THE FUNCTION OF GLYCOPROTEIN IB
|
| Ruggeri Z.M. |
| |
|
THE FUNCTION OF VON WILLEBRAND FACTOR
|
| Sadler J.E. |
| |
|
THE G20210A PROTHROMBIN VARIANT (PT-G20210A) AND THE RISK OF THROMBOEMBOLISM AND FOETAL LOSS IN PREGNANT WOMEN
|
| Tormene D., De Stefano V., Grandone E., Za T., Margaglione M., Martinelli I., Tosetto A., Castaman G., Simioni P. |
| |
|
THE GENETIC ANALYSIS OF DEEP VEIN THROMBOSIS DURING PREGNANCY AND PERINATAL ASSOCIATED DISORDERS IN JAPANESE
|
| Neki R., Ikeda T., Fujita T., Ishikawa J., Sato Y., Miyata T. |
| |
|
THE GENOTYPE BC OF THE VNTR POLIMORPHISM OF THE PLATELET GLYCOPROTEIN IB-ALPHA IS RELATED TO ASPIRIN TREATMENT FAILURE IN PATIENTS WITH ISCHEMIC STROKE
|
| Tassies D., Cervera A., Obach V., Pijoan J., Freire C., Chamorro A., Reverter J.C. |
| |
|
THE GOAL STUDY: A PROSPECTIVE EXAMINATION OF THE IMPACT OF FACTOR V LEIDEN AND ABO (H) BLOOD GROUPS ON HAEMORRHAGIC AND THROMBOTIC PREGNANCY OUTCOMES
|
| Clark P., Walker I.D., Govan L., Wu O., Greer I.A. |
| |
|
THE GPIB-V-IX COMPLEX FACILITATES PLATELET PROCOAGULANT ACTIVITY INDEPENDENTLY OF THE GPIB ALPHA NH2 TERMINAL DOMAIN
|
| Strassel C., Ravanat C., Mangin P., Chicanne G., Payrastre B., Cazenave J.P., Gachet C., Lanza F. |
| |
|
THE HAEMOSTASIS REGISTRY AUSTRALIAN AND NEW ZEALAND EXPERIENCE WITH RFVIIA
|
| Phillips L.E., Isbister J., Dunkley S., McNeil J., Cameron P. |
| |
|
THE HEMOPHILIA REGISTRY OF THE ITALIAN ASSOCIATION OF HEMOPHILIA CENTRES
|
| Iorio A., Gringeri A., Hassan J., Iannaccaro P., Morfini M., Rossetti G., Scaraggi A., Schiavoni M., Schinco P., Tagliaferri A. |
| |
|
THE HEPARIN-BINDING EXOSITE IS CRITICAL TO ALLOSTERIC ACTIVATION OF FACTOR IXA IN THE INTRINSIC TENASE COMPLEX:
|
| Misenheimer T.M., Buyue Y., Sheehan J.P. |
| |
|
THE HUMAN DNMTS1,3A AND 3B MRNA EXPRESSION IN ADULT ITP PATIENTS
|
| Tao J., Chen Z., Yang R. |
| |
|
THE HUMANIZED ANTI-GPIB MONOCLONAL ANTIBODY 6B4-FAB ABOLISHES THROMBUS FORMATION IN A MODIFIED FOLTS' MODEL IN BABOONS
|
| Fontayne A., Staelens S., Meiring M., Lamprecht S., Roodt J., Demarsin E., Barbeaux P., Deckmyn H. |
| |
|
THE HYPERCOAGULABILITY AND VASCULAR ENDOTHELIUM ABNORMAL CYTOKINES' RELEASE MAY INFLUENCE THE PROGRESSION OF THE OSTEOPATHY IN HOMOZYGOUS B-THALASSEMIA PATIENTS
|
| Musso R., Cultrera D., Musso M., Musso A., Meo A., Cipolla A., D'Arpa S. |
| |
|
THE IMPACT OF JOINT BLEEDING AND SYNOVITIS ON PHYSICAL ABILITY AND JOINT FUNCTION
|
| Valentino L.A., Mejia-Carvajal C., Hakobyan N. |
| |
|
THE IMPACT OF PHOSPHOLIPID COMPOSITION ON THE INTERFERENCE CAUSED BY THE ANTIBIOTIC DAPTOMYCIN IN THROMBOPLASTIN REAGENTS
|
| Cawthern K., Bottenus R., Rawal D., Triscott M. |
| |
|
THE IMPLEMENTATION OF A NURSE SPECIALIST MODEL OF CARE IMPROVES VENOUS THROMBOEMBOLISM PROPHYLAXIS RATES IN MEDICAL AND SURGICAL PATIENTS
|
| Collins R., Gibbs H., Gibbs J. |
| |
|
THE IMPORTANCE OF DETECTING ANTI-ADAMTS-13 ANTIBODIES IN PATIENTS WITH SEVERE ADAMTS-13 DEFICIENCY
|
| de Laat B., Groot E., Luken B., de Laaf L., Voorberg J., Eckmann C., van Mourik J., Fijnheer R. |
| |
|
THE IMPORTANCE OF THE PROPEPTIDE FOR CARBOXYLATION OF THE VITAMIN K DEPENDENT CLOTTING FACTORS: STUDIES WITH FACTOR IX
|
| Blostein M.D., Cuerquis J., Landry S., Galipeau J. |
| |
|
THE IMPORTANCE OF TYPE OF QUALITY CONTROL WHEN CHANGING REAGENT BATCHES
|
| Christophe N., Sobas F., Biron C., Benattar N., Negrier C. |
| |
|
THE INCREASE OF INFLAMMATORY MARKERS IN NON-ST-SEGMENT ELEVATION ACUTE CORONARY SYNDROME IS NOT AFFECTED BY GLYCOPROTEIN IIB-IIIA ANTAGONIST EPTIFIBATIDE
|
| Mazaev A.A., Naimushin Y.A., Masenko V.P., Ruda M.Y., Mazurov A.V. |
| |
|
THE INFLUENCE OF DIFFERENT ANTISEPTICS UPON THE IN VITRO PLATELET ACTIVITY IN PATIENTS WITH PERIODONTITIS TREATED BY AUTOLOGOUS PRP TRANSPLANTATION
|
| Vadim T., Orehova L., Vavilova T. |
| |
|
THE INFLUENCE OF FACTOR V LEIDEN AND ABO(H) BLOOD GROUPS ON HAEMATOLOGY PARAMETERS IN EARLY PREGNANCY
|
| Clark P., Walker I.D., Govan L., Wu O., Greer I.A. |
| |
|
THE INFLUENCE OF INTRON 1 SEQUENCE VARIATIONS IN MUTATION- NEGATIVE TYPE 1 VON WILLEBRAND DISEASE PATIENTS
|
| Othman M., Chirinian Y., Brown C., Lillicrap D. |
| |
|
THE INFLUENCE OF STREPTOKINASE ON PLATELETS
|
| Burlova-Vasilieva N.N.K., Volkov G.G.L. |
| |
|
THE INFLUENCE OF THE HEMODIALYSIS PROCEDURES ON PLATELET AND HEMOSTATIC FUNCTIONS
|
| Wang C., Hung S., Jiang J., Chang M., Wu C., Lin T. |
| |
|
THE INFLUENCE OF TISSUE FACTOR ON OESTROGEN RECEPTOR ALPHA EXPRESSION AND CELL INVASION IN BREAST CANCER CELLS
|
| Collier M.E.W., Li C., Frentzou A., Ettelaie C. |
| |
|
THE INFLUENCE OF VON WILLEBRAND FACTOR (VWF) ON FACTOR VIII (FVIII) ACTIVITY IN PLASMA
|
| Butenas S., Parhami-Seren B., Mann K.G. |
| |
|
THE INHIBITORY ACTIVITY AND MECHANISM OF BUD-030, A NOVEL INHIBITOR OF VASCULAR SMOOTH MUSCLE CELLS
|
| Cho K., Hong S., Kang S., Lee T., Chung K. |
| |
|
THE INHIBITORY ACTIVITY OF HEPARIN AND LOW MOLECULAR WEIGHT HEPARIN ON BREAST CARCINOMA CELL LINES
|
| Clutterbuck R.D., Scully M.F., Kakkar A.K. |
| |
|
THE INTERACTION OF KERATINOCYTES AND FIBROBLASTS WITH INTEGRIN ALPHA2BETA1 AGONIST, AGGRETIN, AND ITS REGULATION BETWEEN EPITHELIAL/MESENCHYMAL COMMUNICATION
|
| Chung C.H., Lin K.T., Chang C.H., Huang T.F. |
| |
|
THE INTERACTION OF PROTHROMBIN WITH THE MEMBRANE SURFACE IS A PREREQUISITE FOR OPTIMUM EXPRESSION OF FACTOR VA COFACTOR ACTIVITY WITHIN PROTHROMBINASE
|
| Bukys M.A., Orban T., Kim P.Y., Nesheim M.E., Kalafatis M. |
| |
|
THE INTERNATIONAL NORMALIZED RATIO TO PRIORITIZE PATIENTS FOR LIVER TRANSPLANTATION. PROBLEMS AND SOLUTIONS
|
| Chantarangkul V., Tripodi A., Primignani M., Fabris F., Dell'Era A., Sei C., Mannucci P.M. |
| |
|
THE ISTH SSC VON WILLEBRAND FACTOR (VWF) ONLINE DATABASE
|
| Hampshire D.J., James P.D., Lillicrap D., Peake I.R., Goodeve A.C. |
| |
|
THE KINETICS OF TPA ACTIVACTION AND INHIBTION BY PAI-1 IN FIBRIN
|
| Longstaff C., Kolev K., Thelwell C. |
| |
|
THE KOGEOGPK PEPTIDE FROM TYPE III COLLAGEN INHIBITS BREAST ADENOCARCINOMA CELL ADHESION TO TYPE III COLLAGEN AND HUVEC MATRIX IN WHOLE BLOOD AND UNDER FLOW CONDITIONS
|
| Djaafri I.S., Quinto F., Bruel A., Legrand C., Fauvel-Lafève F. |
| |
|
THE LEECH PRODUCT SARATIN IS A POTENT INHIBITOR OF PLATELET INTEGRIN ALPHA2BETA1 AND VWF BINDING TO COLLAGEN
|
| White T.C., Berny M.A., Robinson D.K., Yin H., DeGrado W.F., Hanson S.R., McCarty O.J.T. |
| |
|
THE LOCALISATION OF A NOVEL FACTOR XIIIB BINDING SITE ON THE ALPHA CHAIN OF FIBRINOGEN AND ITS ROLE IN FXIII DISSOCIATION
|
| Smith K.A., Adamson P.J., Ariens R.A.S., Grant P.J., Philippou H. |
| |
|
THE MANAGEMENT OF HIGH RISK PREGNANT PATIENTS WITH PRIMARY ANTIPHOSPHOLIPID SYNDROME
|
| Ruffatti A., De Silvestro G., Marson P., Pengo V., Bortolati M., Favaro M., Tonello M., Minucci D. |
| |
|
THE MARBURG-1 MUTATION REDUCES THE AUTOCATALYTIC ACTIVITY OF FACTOR SEVEN ACTIVATING PROTEASE (FSAP)
|
| Stavenuiter F., Boon-Spijker M., Clijsters P.P., Mertens K. |
| |
|
THE MECHANISM OF ALLOSTERIC ACTIVATION OF ANTITHROMBIN REVEALED BY CRYSTAL STRUCTURES OF ITS MONOMERIC AND FACTOR XA-COMPLEXED FORMS
|
| Johnson D.J.D., Huntington J.A. |
| |
|
THE MECHANO-REGULATION OF LASP-1 IN THE PATHOGENESIS OF CARDIOVASCULAR DISEASE
|
| Fitzpatrick P., Britto M., Meade G., Cahill P.A., Cummins P.M., Murphy R.P. |
| |
|
THE METHODOLOGICAL PROBLEMS IN BLOOD PLATELET INVESTIGATION ARE STILL ACTUAL
|
| Golanski J., Kuliczkowski W., Dobaczewski M., Watala C. |
| |
|
THE MODIFICATION OF PROTEINS BY NON-EQUILIBRIUM PLASMA THE NOVEL TECHNIQUE FOR THE PRODUCTION OF PLATELET AGGREGATION INHIBITORS
|
| Vasilieva T.M. |
| |
|
THE Na+-BOUND AND Na+-FREE CONFORMATION OF THROMBIN PROBED BY SOLUTION STUDIES
|
| De Filippis V., Pozzi N., Frasson R. |
| |
|
THE NATURAL HISTORY OF D-DIMER LEVELS IN SUBJECTS WITH NEGATIVE D-DIMER AFTER SUSPENSION OF ORAL ANTICOAGULATION FOR A FIRST EPISODE OF VENOUS THROMBOEMBOLISM: THE PROSPECTIVE OBSERVATIONAL PROLONG II STUDY
|
| Cosmi B., Legnani C., Favaretto E., Valdrè L., Mirella F., Giuliana G., Tripodi A., Palareti G. |
| |
|
THE NECESSITY OF CONTINUOUS INDIVIDUAL CALIBRATION IN CONTINUOUS FLUOROGENIC MEASUREMENT OF THE THROMBIN GENERATION CURVE
|
| De Smedt E., Al Dieri R., Spronk H., Hamulyak K., Ten Cate H. |
| |
|
THE NEGATIVE EFFECT OF LEVOBUPIVACAINE ON COLLAGEN-INDUCED PLATELET AGGREGATION
|
| Chang Y., Liao C., Tseng C., Lin Y., Day Y. |
| |
|
THE NIJMEGEN HAEMOSTASIS ASSAY (NHA) IN THE VITRO-STUDY: RELATION WITH HOMOCYSTEINE, B-VITAMIN TREATMENT AND RECURRENCE RISK
|
| den Heijer M., Lap P., Loof A., van Heerde W.L. |
| |
|
THE NON-CATALYTIC SIGNALLING FUNCTION OF PI 3-KINASE P110GAMMA PROMOTES PLATELET ACTIVATION AND THROMBUS FORMATION
|
| Schoenwaelder S.M., Ono A., Mangin P., Sturgeon S., Chan M., Gachet C., Jackson S.P. |
| |
|
THE NOVEL PROTEIN-PROTEIN INTERACTION IN MAMMALIAN HAEMOSTASIS SYSTEM INDUCING BY STREPTOKINASE
|
| Krasnobryzha I.M., Savchuk O.M., Platonova T.M. |
| |
|
THE OCCURRENCE OF FACTOR V LEIDEN MUTATION IN HUNGARIAN HELLP SYNDROME PATIENTS
|
| Hupuczi P., Nagy B., Szabo G., Berkes E., Rigo B., Sziller I., Papp Z. |
| |
|
THE OMEGA-3 FATTY ACID DOCOSAHEXAENOATE (DHA) REDUCES CYCLOOXYGENASE(COX)-2 INDUCTION BY INHIBITING NADP(H) OXIDASE AND PKC: POSSIBLE INVOLVEMENT OF 15-LIPOXIGENASE(LO)-1
|
| Massaro M., Scoditti E., Carluccio M., Storelli C., Distante A., De Caterina R. |
| |
|
THE ORAL DIRECT THROMBIN INHIBITOR AZD0837 REDUCES THROMBUS FORMATION IN A RAT MODEL
|
| Hockings P.D., Adler G., Palmer M., Andréasson A.C., Elg M. |
| |
|
THE ORAL DIRECT THROMBIN INHIBITOR, DABIGATRAN ETEXILATE, IS EFFECTIVE AND SAFE FOR PREVENTION OF MAJOR VENOUS THROMBOEMBOLISM FOLLOWING MAJOR ORTHOPEDIC SURGERY
|
| Caprini J.A., Hwang E., Hantel S., Schnee J., Eriksson B.I. |
| |
|
THE OUTER-SURFACES OF SCHISTOSOMA MANSONI DURING THE LIFE-CYCLE DEMONSTRATE DIFFERENTIAL PROPERTIES TOWARDS PLATELET ADHESION
|
| Wu Y., van Hellemond J.J., Tielens A.G.M., de Groot P.G., Lenting P.J. |
| |
|
THE P38 MITOGEN-ACTIVATE PROTEIN KINASE MAPK) PATHWAY MEDIATES THE INDUCTION OF TISSUE FACTOR EXPRESSION BY PHOSPHATIDYLSERINE-DEPENDENT ANTIPROTHROMBIN ANTIBODIES WITH LUPUS ANTICOAGULANT ACTIVITY
|
| Oku K., Atsumi T., Amengual O., Kataoka H., Horita T., Yasuda S., Koike T. |
| |
|
THE PERIODONTAL PATHOGEN PORPHYROMONAS GINGIVALIS INDUCES BLOOD COAGULATION THROUGH ACTIVATION OF FACTOR XI BY GINGIPAIN R
|
| Nylander M., Lindahl T.L., Bengtsson T. |
| |
|
THE PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR(PPAR)GAMMA AGONIST ROSIGLITAZONE (RSG) INHIBITS CYCLOOXYGENASE(COX)-2 EXPRESSION BY SUPPRESSING PKCAPLHA AND CREB ACTIVATION
|
| Scoditti E., Massaro M., Carluccio M., Storelli C., Distante A., De Caterina R. |
| |
|
THE PERSISTANCE OF RESIDUAL VEIN THROMBOSIS, AFTER AN EPISODE OF DEEP VEIN THROMBOSIS, AND THE RISK OF NEW OVERT CANCER AND CARDIOVASCULAR DISEASE
|
| Siragusa S., Cigna V., Malato A., Fulfaro F., Lo Coco L., Anastasio R., Abbene I., Saccullo G., Casuccio A. |
| |
|
THE PHARMACOKINETICS OF DEFIBROTIDE IN NON-HUMAN PRIMATES IS DOSE DEPENDENT
|
| Fareed J., Hoppensteadt D., Neville B., McGeehan E., Iacobelli M., Jeske W.P. |
| |
|
THE PHARMACOLOGICAL PROFILE OF DZ-697B, A NOVEL ANTI-PLATELET AGENT
|
| Shibutani T., Muramatsu S., Takahashi S., Kaneda Y., Ogihara Y., Shibano T. |
| |
|
THE PLAQUE LIPID LYSOPHOSPHATIDIC ACID STIMULATES PLATELETS NOT THROUGH THE LPA1, LPA2 AND LPA3 RECEPTOR
|
| Khandoga A.L., Goyal P., Tsukahara R., Wilke N., Miller D.D., Tigyi G., Siess W. |
| |
|
THE PLASMA SAMPLE DILUTION IMPROVES THE CORRELATION BETWEEN REAGENTS FOR PT-METHODS
|
| Osman A., Gustafsson K.M., Lindahl T.L. |
| |
|
THE PLATELET ACTIVATION C-TYPE LECTIN RECEPTOR CLEC-2 SIGNALS VIA A NOVEL YXXL DEPENDENT SIGNALLING CASCADE DISTINCT FROM THAT OF ITAM RECEPTORS
|
| Pearce A.C., Fuller G.L.J., Williams J.A.E., Tomlinson M.G., Eble J.A., Pöhlmann S., Suzuki-Inoue K., Ozaki Y., Watson S.P. |
| |
|
THE PREDICTIVE VALUE OF CRP, D-DIMER AND CLINICAL PROBABILITY TO EXCLUDE DVT IN PERSONS ADMITTED TO HOSPITAL FOR DVT
|
| Esaiasen E., Lægreid I., Vik A., Hansen J.B. |
| |
|
THE PREVALENCE AND BURDEN OF VENOUS THROMBOEMBOLIC DISEASE (VTE) IN SURGICAL PATIENTS IN EUROPE: DATA FROM THE VITAE STUDY
|
| Cohen A.T. |
| |
|
THE PREVALENCE OF SYMPTOMATIC VON WILLEBRAND DISEASE (VWD) IN PRIMARY CARE PRACTICE
|
| James P., Bowman M., Tuttle A., Chirinian Y., Hopman W., Benford K., Rapson D., Lillicrap D. |
| |
|
THE PREVENTION OF THROMBFORMATION UNDER INFLUENCE OF A COMPLEX PREPARATION OF PLANT ANTICOAGULANT
|
| Lyapin G.Yu., Obergan T.Yu. |
| |
|
THE PREVENTION OF THROMBFORMATION UNDER INFLUENCE OF A COMPLEX PREPARATION OF PLANT ANTICOAGULANT
|
| u. Lyapin G.Y., u. Obergan T.Y. |
| |
|
THE PRIORITY TRIAL: PLASMIN REVASCULARIZATION OF ACUTE LOWER EXTREMITY NATIVE ARTERY OR BYPASS GRAFT OCCLUSIONPHASE I/II PROTOCOL DESIGN
|
| Comerota A.J., Marder V.J., Dawkins R. |
| |
|
THE PROCOAGULANT EFFECTS OF PARTICULATE MATTER, A COMPONENT OF AIR POLUTION, IN THE LUNGS
|
| Frederix K., Kooter I.M., Gerlofs-Nijland M.E., van Oerle R., Hamulyak K., ten Cate H., Spronk H.M.H. |
| |
|
THE PROGRESS AND CHARACTERISTICS OF DISSEMINATED INTRAVASCULAR COAGULATION DIAGNOSED BY NEWLY ESTABLISHED DIAGNOSTIC CRITERIA FOR CRITICALLY ILL PATIENTS
|
| Gando S., Saito D., Mayumi T., Ogura H., Koseki K., Ikeda T., Ishikura H., Iba T., Ueyama M., Eguchi Y., Ohtomo Y., Okamoto K., Kushimoto S., Endo S., Shimazaki S. |
| |
|
THE PROTECTIVE EFFECT OF FXIII VAL34LEU POLYMORPHISM AGAINST VENOUS THROMBOSIS IN IRANIAN PATIENTS
|
| Sajadi S., Samiei S., Kheirandish M., Ataiei Z., Kavari M., Abdollahi M., Tootian S., Soheily Z., Tabatabaie S., Meshkani R., Sharifi Z., Jalali Far M. |
| |
|
THE PROTECTIVE ROLE OF PROTEIN C IN ENDOTOXIN-INDUCED SHOCK
|
| Lay A.J., Donahue D., Tsai M., Castellino F.J. |
| |
|
THE PROTEIN S THROMBIN SENSITIVE REGION CONTRIBUTES REGULATION OF WARFARIN TREATED DES-GAMMA-CARBOXYLATED PROTEIN S SECRETION: A STUDY OF A NOVEL SPLICE SITE MUTATION OF PROTEIN S GENE AND ITS MOLECULAR CONSEQUENCES
|
| Okada H., Kunishima S., Hamaguchi M., Takagi A., Yamamoto K., Takamatsu J., Matsushita T., Saito H., Kojima T., Yamazaki T. |
| |
|
THE PROTHROMBOTIC AND HYPERTENSIVE EFFECTS OF ANGIOTENSIN(1-9) IN RATS MAY BE MEDIATED BY ANGIOTENSIN II
|
| Mogielnicki A., Kramkowski K., Pawlak D., Buczko W. |
| |
|
THE PROTOCOL FOR DIAGNOSTICS AND INTENSIVE CARE OF DISSEMINATED INTRAVASCULAR COAGULATION SYNDROME
|
| Zabolotskikh I.B., Sinkov S.V. |
| |
|
THE PTT IS NOT ENOUGH PREOPERATIVE COAGULATION SCREENING IN CHILDREN
|
| Bidlingmaier C., Sax F., Treutwein J., Kurnik K. |
| |
|
THE QUALITY OF ANTICOAGULATION ON FUNCTIONAL OUTCOME AND MORTALITY FOR TIA/STROKE IN ATRIAL FIBRILLATION PATIENTS
|
| Poli D., Antonucci E., Fatini C., Ciucciarelli L., Sticchi E., Corsi A., Abdullahi Said A., Abbate R., Gensini G., Prisco D. |
| |
|
THE RAPID PROCOAGULANT MEMBRANE SCRAMBLING INDUCED BY CALCIUM IONOPHORES IN PLATELETS AND LYMPHOCYTES IS DIFFERENT FROM THAT INDUCED BY THAPSIGARGIN IN PLATELETS: DEMONSTRATION WITH CYCLOSPORIN A
|
| Kerbiriou-Nabias D.M., Arachiche A., Garcin I., Combettes L., Geldwerth D., Freyssinet J.M., Letellier T., Dachary-Prigent J. |
| |
|
THE RECEPTORS OF PROTEIN C ACTIVATION AND ACTIVATED PROTEIN C SIGNALING PATHWAYS ARE CO-LOCALIZED IN LIPID RAFTS OF ENDOTHELIAL CELLS
|
| Bae J., Yang L., Rezaie A.R. |
| |
|
THE REGULATION OF ENDOTHELIAL CELL T-PA PRODUCTION BY FLUVASTATIN
|
| Fish R.J., Dunoyer-Geindre S., Kruithof E.K.O. |
| |
|
THE REGULATION OF THROMBOMODULIN DISTRIBUTION IN ENDOTHELIAL CELLS
|
| Chen P., Huang C., Lien Y., Shi G., Wu H. |
| |
|
THE RELATION OF HIGH EX VIVO THROMBOGENIC POTENTIAL TO HIGH ISCHEMIC RISK IN AFRICAN AMERICAN WOMEN UNDERGOING CORONARY STENTING
|
| Bliden K.P., Kreutz R.P., Tantry U.S., Gurbel P.A. |
| |
|
THE RELATIONSHIP BETWEEN STRANDING IN CARS AND DVT AFTER THE MIDDLE NIIGATA PREFECTURE EARTHQUAKE 2004
|
| Hanzawa K., Tsuchida K., Kitajima I., Nakajima T., Hayashi J. |
| |
|
THE RELATIONSHIP OF P2Y1 ADP RECEPTOR POLYMORPHISMS AND ISCHEMIC VASCULAR DISEASE
|
| Park E., Park S., Kim I., Yoon S., Park S., Park J., Yun-Choi H., Kim J., Park S., Hong Y., Lee S. |
| |
|
THE RELATIVE EFFECTS OF VKORC1 AND CYP2C9 VARIANTS ON CLINICAL OUTCOMES IN WARFARIN PATIENTS
|
| Meckley L.M., Wittkowsky A.K., Rieder M.J., Rettie A.E., Veenstra D.L. |
| |
|
THE RESULTS OF OUR FEBRILE NEUTROPENIA MANAGEMENT REPORTS FOR THREE YEARS
|
| Sayilan Sen H.H.S., Salcioglu Z., Akici F., Aydogan G., Ulucakli O., Yanilmaz O., Aktay Ayaz N., Aldemir H. |
| |
|
THE RGD-CONTAINING PEPTIDE DERIVED FROM PLATELET DISABLED-2 INHIBITS DU145 PROSTATE CANCER CELL-INDUCED PLATELET AGGREGATION
|
| Tseng C., Chen L., Huang C., Liao C., Cheng J. |
| |
|
THE RGDS SEQUENCE OF THE ANTICOAGULANT PROTEIN C (PC) CONTRIBUTES TO ITS ENDOTHELIAL CELL RECEPTOR (EPCR) BINDING
|
| Saposnik B., Vermillard V., Bachelot-Loza C., Borgel D., Aiach M., Gandrille S. |
| |
|
THE RISK FACTORS FOR THROMBOEMBOLISM IN PATIENTS WITH MECHANICAL VALVE
|
| Omori H., Murasaki K.M., Uetsuka Y., Hagiwara N., Kasanuki H. |
| |
|
THE RISK FOR THROMBOEMBOLIC DISEASE IN LUPUS ANTICOAGULANT PATIENTS DUE TO PATHWAYS INVOLVING P-SELECTIN AND CD154
|
| Bugert P., Pabinger I., Stamer K., Vormittag R., Skeate R.C., Wahi M.M., Klüter H., Panzer S. |
| |
|
THE RISK OF FATAL PULMONARY EMBOLISM AFTER STOPPING ANTICOAGULANT THERAPY IN PATIENTS WITH VENOUS THROMBOEMBOLISM
|
| Douketis J., Gu C., Schulman S., Ghirarduzzi A., Pengo V., Prandoni P. |
| |
|
THE RISK OF INHIBITOR DEVELOPMENT IN 1104 PATIENTS WITH HEMOPHILIA A ACCORDING TO FACTOR VIII GENOTYPE
|
| Boekhorst J., Rastegar Lari G., d'Oiron R., Costa J.M., Novakova I.R.O., Ala F.A., Lavergne J.M., van Heerde W.L. |
| |
|
THE RISK OF PREGNANCY-RELATED VENOUS THROMBOEMBOLISM IN DOUBLE CARRIERS OF FACTOR V LEIDEN AND PROTHROMBIN G20210A
|
| Battaglioli T., De Stefano V., Tormene D., Valdré L., Grandone E., Tosetto A., Martinelli I. |
| |
|
THE RISK OF RECURRENT VENOUS DISEASE ASSOCIATED WITH INFLAMMATORY MARKERS AND D-DIMER
|
| Vossen C.Y., Christiansen S.C., Cannegieter S.C., Reitsma P.H., Cushman M., Rosendaal F.R. |
| |
|
THE RISK OF RECURRENT VENOUS THROMBOEMBOLISM AFTER DISCONTINUING ANTICOAGULATION IN PATIENTS WITH ACUTE PROXIMAL DEEP VEIN THROMBOSIS OR PULMONARY EMBOLISM. A PROSPECTIVE COHORT STUDY
|
| Prandoni P., Noventa F., Ghirarduzzi A., Pengo V., Bernardi E., Pesavento R., Iotti M., Tormene D., Simioni P., Pagnan A. |
| |
|
THE RISK OF RECURRENT VENOUS THROMBOEMBOLISM AMONG HETEROZYGOUS CARRIERS OF FACTOR V LEIDEN OR PROTHROMBIN G20210A MUTATION. A SYSTEMATIC REVIEW OF PROSPECTIVE STUDIES
|
| Marchiori A., Mosena L., Prins M.H., Prandoni P. |
| |
|
THE RISK OF UNEXPLAINED FOETAL LOSS IS DOSE-DEPENDENTLY RELATED TO THE EXPRESSION OF THE GLY219 VARIANT OF THE ENTOTHELIAL PROTEIN C RECEPTOR BY THE MOTHER, BY THE FATHER AND BY THE COUPLE
|
| Lissalde-Lavigne G., Cochery-Nouvellon E., Mercier E., Balducchi J.P., Ripart-Neveu S., Tailland M.L., Fabbro-Peray P., Daurès J.P., Quéré I., Dauzat M., Marès P., Gris J.C. |
| |
|
THE ROLE OF D-DIMER AS A RISK FACTOR FOR OCCULT CANCER AND CARDIOVASCULAR EVENTS AFTER ANTICOAGULATION WITHDRAWAL FOR A FIRST IDIOPATHIC DEEP VEIN THROMBOSIS IN THE PROLONG STUDY
|
| Cosmi B., Legnani C., Favaretto E., Guazzaloca G., Tripodi A., Palareti G. |
| |
|
THE ROLE OF DNA POLYMORPHISMS IN GENES CODING THE HOMOCYSTEINE AND FOLATE METABOLIZING ENZYMES IN ISCHAEMIC HEART DISEASE
|
| Klenkova N.A., Kapustin S.I., Smirnova O.A., Shmeleva V.M., Papayan L.P., Blinov M.N. |
| |
|
THE ROLE OF FACTOR VIII IN THE DEVELOPMENT OF ATHEROSCLEROTIC LESIONS IN MURINE MODELS
|
| Fabri D.R., Annichino-Bizzacchi J.M., Costa D.S.P., Arruda V.R. |
| |
|
THE ROLE OF FC-GAMMA RECEPTOR GENE POLYMORPHISMS IN THE CLINICAL OUTCOME OF NEWLY DIAGNOSED ITP IN CHILDREN
|
| Tarantino M.D., Streater G., Pumfrey L., Williams S., Nugent D. |
| |
|
THE ROLE OF HIT PLATELET FACTOR 4 ANTIGENIC COMPLEXES ON MONOCYTE SURFACES IN THE PATHOGENESIS OF HEPARIN-INDUCED THROMBOCYTOPENIA
|
| Rauova L., Cines D.B., Poncz M. |
| |
|
THE ROLE OF MICROPARTICLES IN GESTATIONAL VASCULAR COMPLICATIONS
|
| Aharon A., Tamari T., Brenner B. |
| |
|
THE ROLE OF PLATELET GLYCOPROTEIN VI IN ARTERIAL THROMBOSIS
|
| Marchese P., Almus-Jacobs F., Cheli Y., Ware J., Kunicki T.J., Ruggeri Z.M. |
| |
|
THE ROLE OF PLATELET MICROPARTICLES IN ANGIOGENESIS AND TUMOR BIOLOGY
|
| Brill A., Dashevsky O., Zelikovitz T., Varon D. |
| |
|
THE ROLE OF RACE AND ETHNICITY IN THE CLINICAL OUTCOMES OF SEVERE HEMOPHILIA A PATIENTS WITH INHIBITORS
|
| Kruse-Jarres R., Pajewski N.M., Leissinger C.A. |
| |
|
THE ROLE OF THE ACIDIC COOH-TERMINAL REGION OF FACTOR VA HEAVY CHAIN DURING ACTIVATION OF PROTHROMBIN BY PROTHROMBINASE
|
| Hirbawi J., Bukys M.A., Orban T., Barhoover M.A., Kalafatis M. |
| |
|
THE ROLE OF THE FACTOR V B DOMAIN IN FACTOR V-MMRN1 BINDING AND DISSOCIATION
|
| Jeimy S.B., Fuller N., Tasneem S., Quinn-Allen M., Zhu H., Camire R.M., Kane W.H., Hayward C.P.M. |
| |
|
THE ROLE OF THE LOW-DENSITY LIPOPROTEIN RECEPTOR-RELATED PROTEIN (LRP) AND MEGALIN RECEPTOR IN THE CLEARANCE OF FACTOR VIII IN HUMANS
|
| Boekhorst J., Lap P.A.J., van Hoogen P.C.M., van Kraaij M.G.J., Novakova I.R.O., Verbruggen B., van Heerde W.L. |
| |
|
THE ROLE OF THROMBIN EXOSITES I AND II IN THE ACTIVATION OF HUMAN COAGULATION FACTOR V
|
| Segers K., Dahlbäck B., Bock P.E., Tans G., Rosing J., Nicolaes G.A.F. |
| |
|
THE ROLES OF SERUM MATRIX METALLOPROTEINASES IN PATIENTS WITH CORONARY ARTERY DISEASE AND ATRIAL FIBRILLATION TO HEART FAILURE
|
| Jong G., Ma T. |
| |
|
THE ROLES OF TUMOR NECROSIS FACTOR-? AND CELL ADHESION MOLECULES IN PATIENTS WITH ACUTE MYOCARDIAL INFARCTION AND HEART FAILURE
|
| Ma T., Jong G. |
| |
|
THE SAFETY OF ANTICOAGULANTS IN PEDIATRIC ARTERIAL ISCHEMIC STROKE: PRELIMINARY RESULTS
|
| Finkelstein T.S., Brandao L.R., Kirton A., Chan A.K., Williams S., MacGregor D., Finkelstein Y., Pontigon A., Adams M., deVeber G. |
| |
|
THE SCREEN OF INHERITED ANTICOAGULANT PROTEINS DEFICIENCY AMONG NORMAL CHINESE
|
| Wei X., Ding Q., Wang X., Wang H. |
| |
|
THE SCREENING ASSAY OF PLATELET- ASSOCIATED IMMUNOGLOBULIN G CAN NOT IMPROVE THE SENSITIVITY OF MONOCLONAL ANTIBODY IMMOBILIZATION OF PLATELET ANTIGENS ASSAY IN IMMUNE THROMBOCYTOPENIC PURPURA
|
| Yi C.H., Hou M., Zhu Y.Y., Qin P. |
| |
|
THE SIGNIFICANCE OF BREAKPOINT DELINEATION IN LARGE DELETIONS IN THE F8 GENE
|
| Cutler J.A., Bourdon L., Ball S., Rangarajan S., Mitchell M. |
| |
|
THE SPECTRUM OF THE PLATELET RESPONSE
|
| Goodall A.H. |
| |
|
THE SPLENIC MICRO-ENVIRONMENT AND FVIII-VWF INTERACTION ARE DETERMINANTS OF THE IMMUNOGENIC PRESENTATION OF FVIII BY DENDRITIC CELLS
|
| Qadura M., Othman M., Burnet E., Waters B., Hough C., Lillicrap D. |
| |
|
THE SSC/ISTH SECONDARY COAGULATION STANDARD LOT#3 IN UK NEQAS FOR BLOOD COAGULATION PROFICIENCY TESTING EXERCISES: MARKED DIFFERENCES IN FV AND FXI RESULTS BETWEEN COMMERCIAL REFERENCE PLASMAS
|
| Woods T.A., Jennings I., Kitchen S., Kitchen D.P., Walker I.D. |
| |
|
THE STABILITY OF A PLASMA-DERIVED FACTOR VIII PRODUCT DURING SIMULATED CONTINUOUS INFUSION
|
| Pham H., Tzouroutis J., Martinelli T. |
| |
|
THE SYNERGISTIC EFFECTS OF SYNTHETIC PHOSPHOLIPIDS AND RECOMBINANT TISSUE FACTOR IN THE OPTIMIZATION OF A PROTEIN S ASSAY SENSITIVITY
|
| Bottenus R., Cao Z., Safa O., Vasquez J., Triscott M. |
| |
|
THE T ALLELE OF THE FXII 46C/T GENE POLYMORPHISM IS RISK FACTOR FOR ICD IN SPANISH POPULATION
|
| Moreno V.P., García-Raso A., García-Bueno M.J., Sánchez C., Drozdowskyj A., García-Torres A., Subirá D., Llamas P. |
| |
|
THE THERAPEUTICAL STRATEGIES ARE EFFECTIVE TO PREVENT THE RECURRENT ABORTIONS, REPEATED FETAL LOSS OR THE INTRAUTERINE FETAL GROWTH RETARDATION IN WOMEN WITH COAGULATION ABNORMALITIES AND/OR GENETIC THROMBOPHILIC MUTATIONS
|
| Musso R., Nardo F., Cultrera D., Sortino G., Azzaro M., Cipolla A., Di Francesco E., Musso M., Musso A. |
| |
|
THE THROMBIN ENDOTHELIAL RECEPTORS, THROMBOMODULIN AND PAR-1, ACTIVATE EGF RECEPTOR THROUGH DISTINCT SIGNALLING
|
| Chieng-Yane P., Millanvoye-Van Brussel E., Le Bonniec B., David-Dufilho M., Rendu F. |
| |
|
THE THROMBIN GENERATION TEST NEEDS TO BE SUPPLEMENTED WITH ADDITIONAL TESTS TO FULLY DOCUMENT THE EFFECTS OF THROMBIN INHIBITORS: EVALUATION FOR MELAGATRAN
|
| Kluft C., Meijer P., Kret R. |
| |
|
THE THROMBIN MUTANT W215A/E217A ACTS AS A PLATELET ANTAGONIST THROUGH INHIBITION OF THROMBIN ACTIVATION AND GPIB BINDING TO VWF
|
| Berny M.A., White T.C., Tucker E.I., Di Cera E., Gruber A., McCarty O.J.T. |
| |
|
THE THROMBOMODULIN PROTEIN C SYSTEM PROTECTS AGAINST DIABETIC NEUROPATHY VIA TWO INDEPENDENT MECHANISMS
|
| Isermann B., Blautzik J., Vinnikov I., Herzog S., Weiler H., Bierhaus A., Nawroth P.P. |
| |
|
THE TIGHT JUNCTION PROTEIN ESAM IS RECRUITED TO PLATELET-PLATELET CONTACTS AND FORMS SIGNALING COMPLEXES THAT AFFECT THROMBUS GROWTH AND STABILITY
|
| Stalker T.J., Wu J., Hall R.A., Brass L.F. |
| |
|
THE TIME COURSES OF FIBRIN FORMATION, PROTHROMBIN ACTIVATION AND TAFI ACTIVATION IN NORMAL AND FACTOR VIII-DEFICIENT PLASMA
|
| Foley J.H., Nesheim M.E. |
| |
|
THE TISSUE FACTOR CYTOPLASMIC DOMAIN REGULATES PROCOAGULANT RESPONSES IN MACROPHAGES
|
| Ahamed J., Niessen F., Kurokawa T., Lee Y.K., Bhattacharjee G., Morrissey J.H., Ruf W. |
| |
|
THE TRANSCRIPTION FACTOR EGR-1 PLAYS A CRITICAL ROLE IN ANTIPHOSPHOLIPID ANTIBODY-MEDIATED THROMBOSIS
|
| Kinev A.V., Romay-Penabad Z., Liu X., Pierangeli S.S., Roubey R.A.S. |
| |
|
THE TYPE OF MANIFESTATION OF THE ANTIPHOSPHOLIPID SYNDROME IN RELATION TO THE AGE OF THE PATIENTS
|
| Miesbach W., Hudek R., Asmelash G., Llugalio B., Scharrer I., Grossmann R. |
| |
|
THE UK NATIONAL EXTERNAL QUALITY ASSESSMENT SCHEME (UK NEQAS) FOR MOLECULAR GENETIC TESTING IN HAEMOPHILIA
|
| Perry D.J., Goodeve A., Hill M., Jennings I., Kitchen S., Walker I. |
| |
|
THE UREMIC SOLUTE INDOXYL SULFATE INDUCES OXIDATIVE STRESS IN ENDOTHELIAL CELLS
|
| Dou L., Jourde-Chiche N., Cerini C., Berland Y., Brunet P., Dignat-George F. |
| |
|
THE UROKINASE RECEPTOR: CELL MIGRATION, CELL PROLIFERATION AND CANCER
|
| Blasi F. |
| |
|
THE UROKINASE SYSTEM REGULATES THE MOBILIZATION, HOMING AND DIFFERENTIATION OF PROGENITOR CELLS INTO ENDOTHELIAL CELLS
|
| Rentala S., Daniel J.M., Uslu Ö., Preissner K.T., Sedding D., Kanse S.M. |
| |
|
THE USE OF ADVATE IN LIVER AND KIDNEY TRANSPLANTATION IN A PATIENT WITH HEMOPHILIA A, HEPATITIS C, AND HIV
|
| Boggio L.N., Harris S.A., Fryer J., Zakarija A. |
| |
|
THE USE OF ATOMIC FORCE MICROSCOPY TO STUDY COLLAGEN-PLATELET INTERACTIONS
|
| Simpson A.M.C., Farndale R.W., Shahin V. |
| |
|
THE USE OF FEIBA DURING SURGERIES IN HAEMOPHILIA PATIENTS WITH INHIBITORS TO FACTOR VIII AND IX
|
| Negrier C., Fleury R., Hoots K.W., Gajek H., Berg R., Stephens D., Skvortsova E. |
| |
|
THE USE OF HAEMOSTASIS TESTS IN THE FOLOW UP OF A PATIENT WITH ANTITHROMBIN DEFICIENCY DURING THE PREGNANCY AND AFTER DELIVERY
|
| Kovac M., Mikovic D., Rakic L., Maslac A., Mikovic Z., Mandic V. |
| |
|
THE USE OF LOW-MOLECULAR HEPARIN IN PRAGNANTS
|
| Vorobiova E., Pargalava N., Jakeli N., Samladze P. |
| |
|
THE USE OF RITUXIMAB AS AN ADJUVANT THERAPY TO INDUCE IMMUNE TOLERANCE IN CHILDREN WITH HEMOPHILIA A AND B
|
| Chuansumrit A., Sirachainan N., Moonsup Y., Hongeng S., Pakakasama S., Benjaponpitak S., Suebsangad A., Wongwerawattanakoon P. |
| |
|
THE USE OF THE ENDOGENOUS THROMBIN POTENTIAL ASSAY IN THE DIAGNOSIS OF DEEP VENOUS THROMBOSIS
|
| Haas F.J.L.M., Schutgens R.E.G., Kluft C., Biesma D.H. |
| |
|
THE USE OF THE WARKENTIN ET AL 4T CLINICAL SCORING SYSTEM TO DETERMINE PROSPECTIVELY THE APPROPRIATENESS OF HIT ANTIBODY TESTING AT THE REGIONAL HAEMOSTASIS LABORATORY, BELFAST CITY HOSPITAL, N IRELAND
|
| Benson G.M., McNulty O., Cooke P., Murray P., O'Keeffe D. |
| |
|
THE USE OF TISSUE-TYPE PLASMINOGEN ACTIVATOR TO DETECT MISFOLDED PROTEINS IN BIOPHARMACEUTICALS
|
| Maas C., Hermeling S., Bouma B., Jiskoot W., Gebbink M.F.B.G. |
| |
|
THE UTILITY OF QUANTITATIVE CALF MUSCLE NEARINFRARED SPECTROSCOPY IN THE FOLLOWUP OF ACUTE DEEP VEIN THROMBOSIS
|
| Yamaki T., Nozaki M., Sakurai H., Takeuchi M., Soejima K., Kono T. |
| |
|
THE VALUE OF PET- SCANNING IN THE DETECTION OF OCCULT CANCER IN PATIENTS WITH VENOUS THROMBOEMBOLISM
|
| Beckers M., Verzijlbergen J., Tiel-van Buul M., Prins M., Biesma D. |
| |
|
THE VALUE OF ROTEM THROMBOLELASTOMETRY TO DETECT DISTURBED HAEMOSTASIS AND BLEEDING RISK IN ON-PUMP CARDIAC SURGERY
|
| Lösche W., Reinhöfer M., Macholdt C., Brauer M., Gummert J., Barz D., Marx G. |
| |
|
THE VISCOELASTIC PROPERTIES OF SINGLE, CROSSLINKED AND UNCROSSLINKED FIBRIN FIBERS
|
| Guthold M., Liu W., Sparks E.A., Carlisle C., Hantgan R.R., Falvo M.R., Superfine R., Lord S.T. |
| |
|
THE VITAMIN K EPOXIDE REDUCTASE GENE POLYMORPHISMS AND PHARMACOGENETICS OF WARFARIN
|
| Sirotkina O., Ulitina A., Markov A., Vavilova T. |
| |
|
THE VON WILLEBRAND FACTOR (VWF) AND FACTOR VIII ACTIVITIES VERSUS VWF ANTIGEN RATIOS IN PATIENTS WITH VON WILLEBRAND DISEASE TYPE 1: RESULTS FROM THE EUROPEAN MULTICENTER MCMDM-1VWD STUDY
|
| Federici A.B., Tosertto A., Eikenboom J.C., Goodeve A., Budde U., Bader R., Canciani M.T., Castaman G., Battle J., Meyer D., Mazurier C., Goudemand J., Schneppenheim R., Ingerslev J., Vorlova Z., Habart D., Holmberg L., Lethagen S., Pasi J., Hill F., Rodeghiero F., Peake I.R. |
| |
|
THE VWF-GPIB AXIS AS A THERAPEUTIC TARGET
|
| Deckmyn H., De Meyer S., Feys H., Salles I., Vanhoorelbeke K. |
| |
|
THE Y2561 ALLELE OF A COMMON POLYMORPHISM IN THE C1 DOMAIN OF VON WILLEBRAND FACTOR APPEARS AS A NOVEL RISK FACTOR FOR MYOCARDIAL INFARCTION
|
| Hellermann N., Boehm B.O., Maerz W., Rischewski J., Winkelmann B.R., Zotz R.B., Schneppenheim R. |
| |
|
THE ZYMOGEN PROCARBOXYPEPTIDASE U (TAFI) DOES NOT INFLUENCE THE FIBRINOLYTIC RATE
|
| Willemse J.L., Heylen E., Hendriks D.F. |
| |
|
THERAPEUTIC ANTIBODIES AGAINST CD40 LIGAND, TNF-ALPHA AND VEGF SHARE MECHANISTIC FEATURES IN COMMON WITH PLATELET ACTIVATING ANTIBODIES IN HEPARIN-INDUCED THROMBOCYTOPENIA (HIT)
|
| Davila M., Meyer T., Langer F., Robson T., Robles L., Desai H., Amirkhosravi A., Amaya M., Elias P., Francis J. |
| |
|
THERAPEUTIC DRUG MONITORING OF HEPARINS AND DIRECT THROMBIN INHIBITORS: THE GERMAN EXTERNAL QUALITY ASSESSMENT SCHEME
|
| Peetz D., Dick A., Spannagl M. |
| |
|
THERAPY OF ACQUIRED HEMOPHILIA HAS CYTOTOXIC AND RITUXIMAB TREATMENT TO BE COMBINED WITH IMMUNOADSORPTION?
|
| Wolf H.H., Frühauf A., Schmoll H.J. |
| |
|
THIOSULFINATES MODULATE PLATELET ACTIVATION AND MONOCYTE FUNCTION BY REACTION WITH SURFACE FREE SULFHYDRYLS AND INTERNAL THIOL-CONTAINING PROTEINS
|
| Merhi F., Badol P., David-Dufilho M., Bauvois B., Rendu F. |
| |
|
THREE DIFFERENT PATTERNS OF CALIBRATED AUTOMATED THROMBOGRAM OBTAINED WITH HIRUDIN, MELAGATRAN, DABIGATRAN, ARGATROBAN, FONDAPARINUX AND DANAPAROD
|
| Samama M.M., Le Flem L., Guinet C., Depasse F. |
| |
|
THREE NEW MUTATIONS IN FXII DEFICIENCY
|
| Lombardi A., Bortoletto E., Scapin M., Scarparo P., Girolami A. |
| |
|
THREE NEW POLYMORPHISMS LOCATED IN THE INTRON 2 OF THE ADAMTS13 GENE
|
| Kempfer A., Keller L., Farias C., Woods A., Sanchez-Luceros A., Powazniak Y., Carrivale M., Lazzari M. |
| |
|
THREE NOVEL MUTATIONS OF ANTITHROMBIN GENE WERE IDENTIFIED IN CHINESE FAMILIES
|
| Yang F., Wang X., Jin P., Wang H. |
| |
|
THREE RESIDUES (L284, I290, Y329) IN THE APPLE 4 DOMAIN OF FACTOR XI (FXI) ARE ESSENTIAL FOR COVALENT DIMERIZATION OF FXI SUBUNITS
|
| Zucker M., Zivelin A., Landau M., Rosenberg N., Seligsohn U. |
| |
|
THREE-MONTH INCIDENCE OF VENOUS THROMBOEMBOLISM (VTE) IN PATIENTS WITH ISOLATED SUPERFICIAL THROMBOPHLEBITIS (ST): PRELIMINARY RESULTS OF THE POST STUDY
|
| Decousus H., Quéré I., Leizorovicz A. |
| |
|
THRESHOLD BEHAVIOR OF THE BLOOD CLOTTING SYSTEM ACTIVATED BY THE TISSUE FACTOR
|
| Balandina A.N., Kireev D.A., Panteleev M.A., Shmirev I.I., Shibeko A.M., Ataullakhanov F.I. |
| |
|
THROMBELASTOGRAPHY MAY NOT ALWAYS DETECT CLINICALLY RELEVANT FACTOR XIII DEFICIENCY
|
| Moessmer G. |
| |
|
THROMBELASTOGRAPHY STUDY OF HEMOSTATIC AGENTS
|
| Peng H.T., Blostein M.D., Gamble D., Huang H., Shek P.N. |
| |
|
THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR (TAFI) GENE POLYMORPHISM AND RISK FOR VENOUS THROMBOSIS DISEASE (VTD)
|
| Verdu J.B., Marco P., Brocal I., Lucas J., Benlloch I. |
| |
|
THROMBIN ACTIVATABLE FIBRINOLYSIS INHIBITOR (TAFI) THR325ILE AND FACTOR XII C46T POLYMORPHISMS IN ATHEROSCLEROTIC RENAL ARTERY STENOSIS
|
| Smid M., Plat A.W., Stoffers H.E.J.H., Spronk H.M.H., de Leeuw P.W., Kroon A.A., ten Cate H. |
| |
|
THROMBIN ACTIVATBLE FIBRINOLYSIS INHIBITOR (TAFI) IS NOT ASSOCIATED WITH FETAL LOSS; A RETROSPECTIVE STUDY
|
| Folkeringa N., Korteweg F.J., Veeger N.J.G.M., Erwich J.H.M., van der Meer J. |
| |
|
THROMBIN ACTIVITY PROFILE: A POWERFUL EX VIVO SCREENING TEST FOR THE DEVELOPMENT OF ANTICOAGULANT DRUGS
|
| Robert S., Ghiotto J., Pirotte B., David J.L., Masereel B., Pochet L., Dogne J.M. |
| |
|
THROMBIN ADSORBED TO A FIBRIN CLOT CONFERS ANGIOGENIC AND HEMOSTATIC PROPERTIES ON ENDOTHELIAL PROGENITOR CELLS
|
| Smadja D.M., Amelot A., Bieche I., Le Bonniec B.F., Aiach M., Gaussem P. |
| |
|
THROMBIN AS PROCOAGULANT AND ANTICOAGULANT
|
| Di Cera E. |
| |
|
THROMBIN BINDING TO GLYCOPROTEIN IB ALPHA ON PLATELETS INVOLVES EXOSITE I
|
| Yegneswaran S., Roberts J.R., Ruggeri Z.M. |
| |
|
THROMBIN CONCENTRATION AND PERMEABILITY OF FIBRIN CLOT
|
| Savushkin A.V. |
| |
|
THROMBIN GENERATING CAPACITY IS HIGHLY DECREASED AND DELAYED IN PATIENTS WITH VON WILLEBRAND DISEASE
|
| Rugeri L., Béguin S., Hemker C., Bordet J., Fleury R., Chatard B., Négrier C., Dargaud Y. |
| |
|
THROMBIN GENERATION & ROTEM TESTS IN PREGNANCY: POTENTIAL FOR MONITORING ADEQUACY OF LOW MOLECULAR WEIGHT HEPARIN ADMINISTRATION
|
| Chowdary P., Riddell A., Brooks S., Kelahar N., Moghaddam L., Priest P., Tuddenham E.G. |
| |
|
THROMBIN GENERATION AMONG SUDANESE ESSENTIAL HYPERTENSION PATIENTS
|
| Hassan F.M., Hamid M.M. |
| |
|
THROMBIN GENERATION AND COAGULATION MARKERS IN PATIENTS WITH A FIRST ACUTE MYOCARDIAL INFARCTION
|
| Dielis A.W.J.H., Winkens M.H.M., Spronk H.M.H., Wijers-Holys P.A., van Oerle R., Hamulyák K., Waltenberger J.L., ten Cate H. |
| |
|
THROMBIN GENERATION AND THE TYPE OF ANTITHROMBIN DEFICIENCY
|
| Siegemund A., Scholz U., Thamm-Mücke B., Wittig I., Joel A., Wittig K., Rühlmann C., Siegemund T. |
| |
|
THROMBIN GENERATION ASSAY (TGA) CORRECTION IN VITRO AFTER ADDITION OF THERAPEUTIC RANGE DOSES OF PROTHROMBIN COMPLEX CONCENTRATE (PCC) TO PLASMA SAMPLES WITH INR 5
|
| Jose M., Borrell M., Fontcuberta J., Jorquera J.I. |
| |
|
THROMBIN GENERATION ASSAY: CLINICAL USE IN MONITORING FVIII BYPASSING AGENT THERAPY DURING SURGERY IN A SEVERE HAEMOPHILIA A PATIENT WITH INHIBITOR
|
| N. McCormick Á., Sunner T., Rangarajan S., Savidge G.F. |
| |
|
THROMBIN GENERATION ASSESSMENT: MONITORING OF ANTICOAGULANT EFFECT OF LMWH TREATMENT AFTER STENTING IN PATIENTS WITH CAROTID ARTERY DISEASE
|
| Konstantinidis K., Gerasimidis T., Elalamy I., Verdy E., Samama M., Garypidou V., Gerotziafas G. |
| |
|
THROMBIN GENERATION CAPACITY IS IMPAIRED IN METHYLENE-BLUE (MB) TREATED PLASMA UNITS COMPARED TO SINGLE-DONOR FFP, A PHARMACEUTICALLY LICENSED COAGULATION ACTIVE AND SOLVENT-DETERGENT (S/D) TREATED PLASMA PRODUCT AND A UNIVERSALLY APPLICABLE S/D-PLASMA UN
|
| Pock K., Heger A., Janisch S., Svae T., Roemisch J. |
| |
|
THROMBIN GENERATION IN BEHET'S DISEASE: RELATIONSHIP WITH THROMBOSIS
|
| Reverter J.C., Espinosa G., Bores C., de la Red G., Monteagudo J., Vidaller A., Tassies D. |
| |
|
THROMBIN GENERATION IN CHRONIC MYELOPROLIFERATIVE DISORDERS (MPD)
|
| Marchetti M., Spronk H.M.H., van Oerle R., Vignoli A., Russo L., Ilcheff J., Hamulyak K., Barbui T., Falanga A., ten Cate H. |
| |
|
THROMBIN GENERATION IN CHRONICALLY ANTICOAGULATED PATIENTS
|
| Zolcinski M., Brzezinska-Kolarz B., Undas A., Lelakowski J., Musial J. |
| |
|
THROMBIN GENERATION IN NORMAL UNCOMPLICATED PREGNANCY
|
| Rosenkranz A., Hiden M., Leschnik B., Weiss E., Hofer R., Schlembach D., Lang U., Muntean W.E. |
| |
|
THROMBIN GENERATION IN OBESE CHILDREN AFTER WEIGHT REDUCTION
|
| Hiden M., Mangge H., Rosenkranz A., Cimenti C., Leschnik B., Muntean W. |
| |
|
THROMBIN GENERATION IN PATIENTS AFTER RECENT DEEP VEIN THROMBOSIS VERSUS HEALTHY CONTROLS
|
| ten Cate A.J., Dielis A.W.J.H., Spronk H.M.H., van Oerle R., Hamulyák K., Prins M.H., ten Cate H. |
| |
|
THROMBIN GENERATION IN PATIENTS WITH HAEMOPHILIA AND VWD COMPARISON FLUORIMETRIC METHOD AND ROTEM
|
| Siegemund A., Siegemund T., Saile S., Scholz U., Schoebess R. |
| |
|
THROMBIN GENERATION IN PATIENTS WITH THROMBOPHILIA OR THROMBOSIS AND PREGNANCY
|
| Siegemund A., Siegemund T., Scholz U., Wittig I. |
| |
|
THROMBIN GENERATION IN SEVERE HEMOPHILIACS WITH DIFFERENT CLINICAL PHENOTYPE
|
| Santagostino E., Mancuso M.E., Tripodi A., Chantarangkul V., Clerici M., Sei C., Siboni S.M., Mannucci P.M. |
| |
|
THROMBIN GENERATION PARAMETERS IN A PLATELET-POOR PLASMA MODEL SYSTEM AND THEIR USE IN PATIENTS WITH SINGLE FACTOR DEFICIENCY
|
| Bai B., Wu J.R. |
| |
|
THROMBIN GENERATION PROFILES IN PATIENTS WITH ACUTE CORONARY SYNDROME AND STABLE CORONARY ARTERY DISEASE: A COMPUTATIONAL ANALYSIS
|
| Brummel-Ziedins K., Undas A., Orfeo T., Gissel M., Butenas S., Zmudka K., Mann K.G. |
| |
|
THROMBIN GENERATION TEST AN EXPERIENCE OF ONE CENTRE IN THROMBOPHILIA PATIENTS
|
| Hlusi A., Slavik L., Novak P., Prochazkova J., Krcova V. |
| |
|
THROMBIN GENERATION TEST (TGT) AND ROTATIONAL THROMBOELASTOGRAPHY (ROTEM) AND ITS USE IN ASSESSING SEVERE HAEMOPHILIA A PHENOTYPE
|
| Aghighi S., Riddell A., Chowdary P., Lilley P., Griffioen A., Tuddenham E.G. |
| |
|
THROMBIN GENERATION TEST IN THE MONITORING OF PROTHROMBIN COMPLEX CONCENTRATES
|
| Dargaud Y., Marin S., Bordet J., Poplavsky J., Negrier C. |
| |
|
THROMBIN GENERATION TO MONITOR INHIBITOR BYPASS AGENTS REQUIRES LOW CONCENTRATIONS OF TISSUE FACTOR (TF)
|
| van Veen J.J., Gatt A., Bowyer A., Cooper P.C., Kitchen S., Makris M. |
| |
|
THROMBIN INDUCES ACTIVATION OF MATURED DENDRITIC CELLS VIA RHO/ERK PATHWAYS
|
| Li X., Syrovets T., Paskas S., Laumonnier Y., Simmet T. |
| |
|
THROMBIN INDUCES MMP-10 IN HUMAN ENDOTHELIAL CELLS: PATHOPHYSIOLOGICAL IMPLICATIONS IN DISSEMINATED INTRAVASCULAR COAGULATION
|
| Orbe J., Rodriguez J.A., Montes R., Hermida J., Reverter J.C., Serrano R., Paramo J.A. |
| |
|
THROMBIN IS A ZYMOGEN-LIKE ENZYME
|
| Freund S.M.V., Johnson D.J.D., Huntington J.A. |
| |
|
THROMBIN PROMOTES ANOMALOUS DIFFERENTIATION OF VASCULAR PROGENITOR CELLS DURING NEOINTIMAL HYPERPLASIA AFTER WIRE-INDUCED INJURY
|
| Chen D., Abrahams J.M., Lechler R.I., McVey J.H., Dorling A. |
| |
|
THROMBIN STIMULATES AMP-ACTIVATED PROTEIN KINASE IN ENDOTHELIAL CELLS VIA A CAMKK-BETA-DEPENDENT PATHWAY
|
| Stahmann N., Woods A., Carling D., Heller R. |
| |
|
THROMBIN STIMULATION AMPLIFIES MONOCYTIC/ENDOTHELIAL CELL CROSS-TALK AND SUBSEQUENT MCP-1 RELEASE THROUGH FRACTALKINE BINDING
|
| Laumonnier Y., Popovic M., Burysek L., Syrovets T., Simmet T. |
| |
|
THROMBIN UPREGULATES EXPRESSION OF ONCOSTATIN M (OSM) IN HUMAN MACROPHAGES AND PERIPHERAL BLOOD MONOCYTES
|
| Kastl S.P., Speidl W.S., Katsaros K.M., Kaun C., Huber K., Wojta J. |
| |
|
THROMBIN-INDUCED INTERLEUKIN 1BETA SYNTHESIS IN PLATELET SUSPENSIONS: IMPACT OF CONTAMINATING LEUKOCYTES
|
| Pillitteri D., Scholz T., Kirchmaier C. |
| |
|
THROMBIN-INITIATED PLATELET ACTIVATION IN VIVO IS VON WILLEBRAND FACTOR INDEPENDENT DURING THROMBUS FORMATION IN A LASER INJURY MODEL
|
| Dubois C., Panicot-Dubois L., Gainor J.F., Furie B.C., Furie B. |
| |
|
THROMBIN-MEDIATED IMPAIRMENT OF FGF-2 ACTIVITY
|
| De Cristofaro R., Totta P., Capogrossi M., Facchiano A. |
| |
|
THROMBOCYTE RETRACTION HAS NOT INFLUENCE ON BLOOD CLOT DEFORMABILITY
|
| Savushkin A.V. |
| |
|
THROMBOCYTOPENIA AND CONGENITAL RADIAL DYSPLASIA: A CONTINUUM SPECTRUM OF DISEASES. CASE REPORT
|
| Giordano G., Piano S., Cerletti C., Missere M., Ciuffreda M., Crescente M., Donati M., De Gaetano G., Storti S. |
| |
|
THROMBOCYTOPENIA: ANALYSIS OF 317 PATIENTS
|
| Rothschild C., Cabral E., Garanito M.P. |
| |
|
THROMBOEMBOLISM AND BLEEDING OUTCOMES OF LOW-MOLECULAR-WEIGHT HEPARIN BRIDGING THERAPY DURING PERI-PROCEDURE WARFARIN INTERRUPTION: PATIENT-LEVEL POOLED DATA OF FOUR COHORT STUDIES
|
| Kaatz S., Douketis J.D., Turpie A., Spyropoulos A.C., Dunn A.S. |
| |
|
THROMBOGENICITY OF MICROPARTICLES DERIVED FROM VASCULAR CELLS
|
| Isobe H., Perkmann T., Oskolkova O., Bochkov V., Binder B.R. |
| |
|
THROMBOMODULIN - GUARDING THE VASCULAR ENDOTHELIUM
|
| Conway E.M. |
| |
|
THROMBOMODULIN REGULATES GENE EXPRESSION OF ADHESION MOLECULES ON THE SURFACE OF ENDOTHELIAL CELLS EXPOSED TO HT1080 FIBROSARCOMA CELLS
|
| Horie S., Tabata Y., Ishii H. |
| |
|
THROMBOPATH KIT CORRELATES BETTER WITH FREE PROTEIN S TO PROTHROMBIN RATIO AND FUNCTIONAL PS THAN WITH FREE PS
|
| Smirnov M., Toulon P., Diaz D., Cao Z., Safa O., Triscott M. |
| |
|
THROMBOPATH KIT HAS INCREASED SENSITIVITY TO PROTHROMBOTIC LUPUS ANTICOAGULANTS
|
| Smirnov M., Diaz D., Triscott M., Marlar R. |
| |
|
THROMBOPHILIA & RECURRENT FETAL LOSS: SHOULD WE SCREEN BOTH PARENTS ?
|
| Goubran H.A., Aboulghar M., Gaber K.R., Basha S., Kassim N., Amin S.N., Iskander I.F. |
| |
|
THROMBOPHILIA AND ISCHEMIC STROKE: A RETROSPECTIVE STUDY
|
| Martinez P.A., Garbiero S., Aggio M., Brandt M., Echevarria G., Di Paolo H., Fernandez V., Caferri H., Roumeque L., Bartomioli M. |
| |
|
THROMBOPHILIA AND PREGNANCY COMPLICATIONS: CAUSE OR ASSOCIATION?
|
| Middeldorp S. |
| |
|
THROMBOPHILIA AND SPONTANEOUS ABORTION THERAPY WITH LMW-HEPARI
|
| Fischer R., Fischer R., Zimmermann A., Bohlmann M., Kemkes-Matthes B. |
| |
|
THROMBOPHILIA AS A CAUSE OF UNEXPLAINED FETAL LOSS IN INDIAN PATIENTS AN IN DEPTH STUDY
|
| Vora S., Shetty S., Salvi V., Satoskar P., Ghosh K. |
| |
|
THROMBOPHILIA AS A PREDICTOR OF RESIDUAL VEIN THROMBOSIS. A PROSPECTIVE COHORT STUDY
|
| Spiezia L., Masiero L., Tormene D., Concolato A., Dalla Valle F., Simioni P., Pagnan A., Prandoni P. |
| |
|
THROMBOPHILIA DOES NOT INCREASE THE RISK FOR RECURRENT THROMBOSIS IN PEDIATRIC APS
|
| Berkun Y., Padeh S., Barash J., Uziel Y., Harel L., Mukamel M., Ravel-Vilk S., Kenet G. |
| |
|
THROMBOPHILIA IN HIV-INFECTED PATIENTS WITH OSTEONECROSIS: IS THERE A REAL CONNECTION? THE FIRST CASE-CONTROL STUDY
|
| de Larrañaga G.F., Bottaro E., Martinuzzo M., Iglesias Varela M., Forastiero R., Adamczuk Y., Gómez N., Benetucci J. |
| |
|
THROMBOPHILIA IN PAEDIATRIC CYSTIC FIBROSIS PATIENTS
|
| Williams V.K., Griffiths A.B.M., Martin J., Smith G., Couper R., Revesz T. |
| |
|
THROMBOPHILIA IN PATIENTS WITH CRYPTOGENETIC STROKE AND PATENT FORAMEN OVALE
|
| Offelli P., Zanchetta M., Colonna S., Marzot F., Pengo V. |
| |
|
THROMBOPHILIA IS ASSOCIATED WITH HEPARIN THROMBOPROPHYLAXIS FAILURE IN PATIENTS WITH ACUTE TRAUMATIC SPINAL CORD INJURY
|
| Lubetsky A., Rubin-Asher D., Zeilig G., Ratner A., Asher I., Zivelin A., Seligsohn U. |
| |
|
THROMBOPHILIA IS FREQUENT IN SUPERFICIAL VEIN THROMBOSIS AND IS ASSOCIATED WITH RECURRENCE
|
| Marcucci R., Ciuti G., Poli D., Lenti M., Blagojevic E., Falciani M., Abdullahi A., Gensini G., Abbate R., Prisco D. |
| |
|
THROMBOPHILIA MARKERS IN SYSTEMIC LUPUS ERYTHEMATOSUS A CASE CONTROL STUDY
|
| Ben Romdhane N., Kedous A., Smiti M., Mahjoub S., Kallel H., Zitouni M., Makni S., Fekih M., Kaabachi N., Houmen H. |
| |
|
THROMBOPHILIA RISK FACTORS ARE ASSOCIATED WITH PREGNANCY RELATED THROMBOEMBOLISM
|
| Hvas A., Ingerslev J., Salvig J.D. |
| |
|
THROMBOPHILIA TESTING IN A DEVELOPING COUNTRY REFERRAL CENTER: A 3-YEAR OBSERVATIONAL STUDY
|
| Casais P., Meschengieser S.S., Lazzari M.A. |
| |
|
THROMBOPHILIC POLYMORPHISMS IN PEDIATRIC CATHETER RELATED VERSUS NON CATHETER RELATED VENOUS THROMBOEMBOLISM
|
| Balasa V.V., Kim M., Gruppo R.A. |
| |
|
THROMBOPHILIC RISK FACTORS FOR FIRST VENOUS THROMBOEMBOLISM, RECURRENCE AND ITS IMPLICATIONS: RESULTS FROM A LARGE RETROSPECTIVE FAMILY COHORT STUDY
|
| Lijfering W.M., Coppens M., Veeger N.J.G.M., Middeldorp S., Hamulyák K., Prins M.H., Büller H.R., van der Meer J. |
| |
|
THROMBOPROPHYLAXIS IN ACUTELLY ILL MEDICAL PATIENTS: WHO, WHEN AND HOW
|
| Mismetti P., Laporte S. |
| |
|
THROMBOPROPHYLAXIS IN HIGH-RISK ADOLESCENT INPATIENTS
|
| Raffini L.J., Davis D., Trimarchi T., Martucci M., Manno C. |
| |
|
THROMBOPROPHYLAXIS WITH BEMIPARIN STARTED 6 HOURS AFTER HIP OR KNEE REPLACEMENT SURGERY: REVIEW OF CLINICAL AND POSTMARKETING EXPERIENCE
|
| Martínez-González J., Rocha E., Prandoni P. |
| |
|
THROMBOSIS AND BLEEDING DISORDERS OUTSIDE WESTERN COUNTRIES
|
| Mannucci P.M. |
| |
|
THROMBOSIS AND HEMOSTASIS CENTERS PILOT SITES REGISTRY: MATERNAL THROMBOPHILIA
|
| Thornburg C., Beckman M., Thames E., Brancazio L., Ortel T., James A. |
| |
|
THROMBOSIS AND HEMOSTASIS CENTERS PILOT SITES REGISTRY: THROMBOPHILIA SCREENING IN CHILDREN
|
| Thornburg C., Beckman M., Dowling N., Michaels L., Manco-Johnson M., Pipe S., Kulkarni R. |
| |
|
THROMBOSIS IN BETA THALASSEMIA MAJOR
|
| Faranoush M., Ala F., Vossough P., Rastegarlari G., Jazebi M., Shahshahani T., Hejazi S., Namakian F., Golpayegani M., Hedayatiasl A. |
| |
|
THROMBOSIS IN PATIENTS WITH ANTIPHOSPHOLIPID SYNDROME (APS) DIAGNOSED USING UPDATED CLASSIFICATION CRITERIA
|
| Swadzba J., Musial J., Iwaniec T., Szczeklik A. |
| |
|
THROMBOSIS IN PATIENTS WITH LUNG CANCER AND THE EFFECTIVENESS OF LOW WARFARIN PROPHYLAXIS ON PATIENTS' SURVIVAL
|
| Ciftci A., Altiay G., Demir M., Ozlen B., Hatipoglu O.N., Unlu E., Ekuklu G., Caglar T., Hoppensteadt D., Fareed J. |
| |
|
THROMBOSIS IN PRETERM INFANTS: A REPORT OF FIVE CASES TREATED WITH HIGH DOSE OF TISSUE PLASMINOGEN ACTIVATOR (R-TPA)
|
| Carneiro J.D.A., D'Amico E.A., Matsumoto L.A., Garanito M.P., Santos M.V., Machado R.R., Chamone D.A.F. |
| |
|
THROMBOSIS V.SUBCLAVIAE AND THORACIC OUTLET SYNDROME PAGET-VON SCHROTTER SYNDROME
|
| Jovanoska V.V., Jovanoski I.I.J. |
| |
|
THROMBOSPONDIN-1 (TSP1) PROMOTES THROMBIN GENERATION ON THE SURFACE OF FIBROBLASTS (HS-68) AND INDUCES UPREGULATION OF CONNECTIVE TISSUE GROWTH FACTOR (CTGF) GENE AND PROTEIN EXPRESSION
|
| Manns J.M., Rico M.C., Mason III L.L., DeLa Cadena R.A. |
| |
|
THROMBOSPONDIN1 GENE DEFICIENCY ATTENUATES ATHEROSCLEROTIC PLAQUE BURDEN BUT ACCENTUATES INFLAMMATORY CELL PLAQUE CONTENT IN APOE-DEFICIENT MICE
|
| Moura R., Tjwa M., Vandervoort P., Lawler J., Hoylaerts M. |
| |
|
THROMBOSPONDIN1 GENE DEFICIENCY MODULATES VASCULAR MEDIAL SMOOTH MUSCLE CELL ACTIVATION AND NEOINTIMA FORMATION
|
| Moura R., Tjwa M., Vandervoort P., Lawler J., Hoylaerts M. |
| |
|
THROMBOSPONDIN-1 INHIBITS PLATELET AND MONOCYTE ACTIVATION BY HOCL-OXIDISED PROTEINS
|
| Brodde M.F., Jurk K., Volf I., Van Aken H., Kehrel B.E. |
| |
|
THROMBOSPONDIN-1 MODULATES PLATELET SENSITIVITY TO NITRIC OXIDE
|
| Naseem K.M., Riba R., Roberts W. |
| |
|
THROMBOSTATIN FM19 - A THROMBIN RECEPTOR ACTIVATION ANTAGONIST
|
| Schmaier A.H., Burke F., Warnock M., Nieman M., Hilfinger J., Mosberg H.I. |
| |
|
THROMBOTIC EVENTS IN PATIENTS WITH ELEVATED FVIII LEVEL
|
| Azarkeivan A., Tabatabaie M., Karbasy M., Ahmady Negad M., Maghsoodlu M. |
| |
|
THROMBOTIC MARKERS AND MITRAL VALVE PROLAPSE IN MIGRAINE WITH AND WITHOUT AURA AT CHILDHOOD ONSET
|
| Longoni R., Ondei P., Gamba A., Montani N., Bocchi L., Gamba G. |
| |
|
THROMBOTIC THROMBOCYTOPENIC PURPURA (TTP) FOLLOWING CARDIAC SURGERY: AN EMERGING SYNDROME
|
| Jubelirer S.J., Ratliff H.L., Cotes D.J., Riley M.A., Welch C.A. |
| |
|
THROMBOTIC THROMBOCYTOPENIC PURPURA IN PATIENT WITH LOW ADAMTS-13 ACTIVITY LEVELS BUT NO INHIBITORY AUTOANTIBODIES
|
| Lombardi A., Tezza F., Scarparo P., Vettore S., Scapin M., Randi M., Fabris F. |
| |
|
THROMBOXANE A2/PROSTAGLANDIN H2 RECEPTOR BLOCKER (S18886) SHOWS ANTITHROMBOTIC EFFICACY SIMILAR TO ASPIRIN PLUS CLOPIDOGREL IN STENT-INDUCED THROMBOSIS
|
| Vilahur G., Casaní L., Badimon L. |
| |
|
THROMBOXANE B2 IN PATIENTS WITH A FIRST ACUTE MYOCARDIAL INFARCTION: THE INFLUENCE OF TREATMENT WITH ACETYLSALICYLIC ACID
|
| Dielis A.W.J.H., Winkens M.H.M., Spronk H.M.H., Wijers-Holys P.A., van Oerle R., Hamulyák K., Waltenberger J.L., ten Cate H. |
| |
|
THYROID DISEASES AND THE COAGULATION SYSTEM: A SYSTEMATIC REVIEW
|
| Squizzato A., Romualdi E., Gerdes V.E.A., Buller H.R. |
| |
|
THYROTROPIN-RELEASING HORMONE CHANGE THE PLATELET-ERYTHROCITE INTERACTION AND OSMOTIC FRAGILITY
|
| Golubeva M.G. |
| |
|
TIME COURSE OF COAGULATION FACTORS IN OVERT DISSEMINATED INTRAVASCULAR COAGULATION: A CASE STUDY
|
| Carraro P., Afshar H., Fonnesu B., Plebani M. |
| |
|
TISSUE FACTOR AND COAGULATION FACTOR VII LEVELS DURING ACUTE MYOCARDIAL INFARCTION CONTRIBUTE TO PREDICT MORTALITY AND RE-INFARCTION
|
| Gianluca C., Ferraresi P., Valgimigli M., Malagutti P., Baroni M., Arcozzi C., Gemmati D., Percoco G., Parrinello G., Ferrari R., Bernardi F. |
| |
|
TISSUE FACTOR AND MICROPARTICLES
|
| Mackman N. |
| |
|
TISSUE FACTOR AND TOTAL TISSUE FACTOR PATHWAY INHIBITOR LEVELS IN CORONARY ARTERY DISEASE: CORRELATION WITH THE SEVERITY OF ATHEROMATOSIS
|
| Lima L.M., Sousa M.O., Dusse L.M.S., Lasmar M.C., Lwaleed B.A., Carvalho M.G. |
| |
|
TISSUE FACTOR AROUND DERMAL VESSELS HAS BOUND FACTOR VII IN THE ABSENCE OF INJURY
|
| Hoffman M., Colina C.M., McDonald A.G., Arepally G.M., Pedersen L., Monroe D.M. |
| |
|
TISSUE FACTOR DEPENDENT INITIATION OF PLATELET AND FIBRIN THROMBUS FORMATION
|
| Zampolli A., Ruf W., Ruggeri Z.M. |
| |
|
TISSUE FACTOR GENE TAG-SNPS AND HAPLOTYPES AND THE RISK OF MYOCARDIAL INFARCTION
|
| Quaquaruccio G., Latella M., Graziano M., Di Castelnuovo A., Lorenzet R., Napoleone E., Giannuzzi P., Gattone M., Assanelli D., Novak N., Trevisan M., de Gaetano G., Donati M.B., Iacoviello L. |
| |
|
TISSUE FACTOR INDUCTION BY PROTEASE-ACTIVATED RECEPTOR-1 REQUIRES INTACT CAVEOLIN-ENRICHED MEMBRANE MICRODOMAINS IN HUMAN ENDOTHELIAL CELLS
|
| Banfi C., Brioschi M., Barcella S., Pignieri A., Tremoli E., Parolari A., Biglioli P., Mussoni L. |
| |
|
TISSUE FACTOR PATHWAY INHIBITOR (TFPI) POLYMORPHISMS, HORMONE REPLACEMENT THERAPY (HRT) AND RISK OF VENOUS THROMBOEMBOLISM (VTE)
|
| Andersen T.O., Hoibraaten E., Eilertsen A.L., Sandset P.M. |
| |
|
TISSUE FACTOR PROCOAGULANT ACTIVITY LEVELS IN HUMAN BLOOD ARE ELEVATED BY WARFARIN
|
| Bach R.R., Sun J., Leis L.A., Johnson G.J. |
| |
|
TISSUE FACTOR/FACTOR VIIA COMPLEX REGULATES PDGF-BB-INDUCED CHEMOTAXIS THROUGH SRC FAMILY KINASE SIGNALING
|
| Velling T., Johnell M., Siegbahn A. |
| |
|
TISSUE FACTOR/FACTOR VIIA INHIBITOR REDUCES ISCHEMIA IN PATIENTS WITH NSTE-ACS: FINAL RESULTS OF THE ANTHEM-TIMI 32 TRIAL
|
| Giugliano R.P., Wiviott S.D., Stone P.H., Simon D.I., Schweiger M.J., Bouchard A., Leesar M.A., Goulder M.A., Joing M., Deitcher S.R., McCabe C.H., Braunwald E. |
| |
|
TISSUE FACTOR-DEPENDENT COAGULANT ACTIVITY OF PLATELET-MONOCYTE COMPLEXES IN CHRONIC RENAL FAILURE (CRF). ASSOCIATION WITH HEMOSTATIC ACTIVITY, INFLAMMATION, OXIDATIVE DAMAGE AND ENDOTHELIAL DYSFUNCTION
|
| Panes O., Vásquez L., Martínez C., Tagle R., Pais E., Pereira J., Leighton F., Mezzano D. |
| |
|
TISSUE INHIBITOR OF MATRIX METALLOPROTEINASE 1 (TIMP-1) PREDICTS RESPONSE TO CARDIAC RESYNCHRONIZATION THERAPY IN END STAGE SYSTOLIC HEART FAILURE
|
| Roldan V., Marin F., Martinez J., Hernandez A., Ibañez A., Ortego M., Navarro J., Moro C., Vicente V. |
| |
|
TISSUE PLASMINOGEN ACTIVATOR (RTPA) INDUCED FIBRINOLYSIS - STANDARDIZATION OF METHOD ON THROMBELASTOGRAPHY
|
| Kupesiz O.A., Chitlur M., Rajpurkar M.A., Lusher J., Hollon W., Warrier I. |
| |
|
TISSUE PLASMINOGEN ACTIVATOR AND PLASMINOGEN DOMAINS REGULATING THE POTENCY OF THERAPEUTIC THROMBOLYSIS
|
| Williams S., Longstaff C., Brown K., Thelwell C. |
| |
|
TISSUE PLASMINOGEN ACTIVATOR, PLASMINOGEN ACTIVATOR INHIBITOR-1 AND VON WILLEBRAND FACTOR IN THE ACUTE AND CONVALESCENT PHASE OF ISCHEMIC STROKE
|
| Slavik L., Vlachova I., Herzig R., Krcova V., Bartkova A. |
| |
|
TISSUE TRANSGLUTAMINASE DOES NOT STABILIZE ARTERIAL PLAQUES IN THE APOE DEFICIENT MOUSE
|
| Williams H., Pease R.J., Graham R.M., Jackson C.L., Grant P.J. |
| |
|
TOBACCO SMOKE COOPERATES WITH INTERLEUKIN-1B TO ALTER B-CATENIN TRAFFICKING IN VASCULAR ENDOTHELIUM RESULTING IN INCREASED PERMEABILITY AND INDUCTION OF CYCLOOXYGENASE-2 EXPRESSION IN VITRO AND IN VIVO
|
| Barbieri S.S., Tremoli E., Weksler B.B. |
| |
|
TOLERANCE INDUCTION TO FIX IN MICE WITH PRE-EXISTING ANTI-FIX IMMUNITY FOLLOWING DIRECT INTRAMUSCULAR INJECTION OF AAV
|
| Cohn E.F., Kelly M.E., Zhuo J., Chao H. |
| |
|
TORPID CLINICAL COURSE OF THROMBOTIC THROMBOCYTOPENIC PURPURA
|
| Horvathova D., Batorova A., Jankovicova D., Kotoucek P., Skrakova M., Martinka J., Mistrik M. |
| |
|
TPA IN CHILDREN WITH ARTERIAL ISCHEMIC STROKE: CASES FROM THE IPSS COMPARED WITH LITERATURE-BASED CASES
|
| Amlie-Lefond C., Chan A., Ichord R., deVeber G. |
| |
|
TRANEXAMIC ACID DELAYS THE CLOT LYSIS TIME, AND INCREASES THE ENDOGENOUS THROMBIN GENERATION AND PLASMA PROCARBOXYPEPTIDASE U (TAFI) LEVELS IN PATIENTS WITH MUCOCUTANEOUS BLEEDING
|
| Willemse J.L., Quiroga T., Yin O., Goycoolea M., Panes O., Zuniga P., Matus V., Pereira J., Hendriks D., Mezzano D. |
| |
|
TRANSACTIVATION OF THE INSULIN RECEPTOR MEDIATES PAR-1 RECEPTOR SIGNALLING TO P85 PI3 KINASE/PKB IN HUMAN PLATELETS
|
| Hers I. |
| |
|
TRANSCRIPTOME ANALYSIS OF THE PAR-1 MEDIATED ACTIVATION PATHWAY IN HUMAN MONOCYTES AND INTERACTIONS OF ACTIVATED PROTEIN C
|
| Pereira C., Bachli E.B., Schoedon G. |
| |
|
TRANSDUCTION OF COLONIC EPITHELIUM IN SEVERE HEMOPHILIA B BY NONINVASIVE APPROACH WITH RAAV2-HFIX RESULTED IN TRANSIENT EXPRESSION
|
| Chen F., Zhou S., Peng J., Wu X., Xie Q. |
| |
|
TRANSFUSION OF FRESH FROZEN PLASMA AND PLATELETS TO ACHIEVE HEMOSTASIS DURING CARDIOVASCULAR SURGERY INCREASES THE RISK OF POSTOPERATIVE INFECTION
|
| Iwade M., Nomura M., Ozaki M., Seino Y., Shoji S., Iwade K. |
| |
|
TRANSIENT ACTIVATION OF BLOOD COAGULATION FACTOR XIII BY POLYMORPHONUCLEAR GRANULOCYTE ELASTASE
|
| Bagoly Z., Fazakas F., Haramura G., Tóth E., Muszbek L. |
| |
|
TRANSIENT REVERSAL OF THE ANTI-PLATELET EFFECT OF ASPIRIN AFTER ADMINISTRATION OF UNFRACTIONATED HEPARIN IN HEALTHY SUBJECTS
|
| Sheehan N.R., McMahon G., Chambers C., James T.E., Jones C.I., Goodall A.H. |
| |
|
TRANSITION TO AN UNSTABLE CORONARY SYNDROME IS MARKED BY HYPERCOAGUABILITY, PLATELET ACTIVATION, HEIGHTENED PLATELET REACTIVITY, AND INFLAMMATION: RESULTS OF THE THROMBOTIC RISK PROGRESSION (TRIP) STUDY
|
| Tantry U.S., Bliden K.P., Kreutz R.P., DiChiara J., Gurbel P.A. |
| |
|
TRANSITION TO STANDARD HAEMOSTATIC THERAPY SCHEMES OF HEMOPHILIA IN RUSSIA (THE NATIONAL TREATMENT PROTOCOL FOR HEMOPHILIA PATIENTS)
|
| Kudryavceva L., Plyushch O., Kopylov K., Tentsova I., Likhacheva E., Lopatina E. |
| |
|
TRANSPLANT BONE MARROW THAT IS GENETICALLY MODIFIED TO EXPRESS FVIII ONLY IN PLATELETS CAN RESTORE HEMOSTASIS TO HEMOPHILIA A MICE ON A STRONG INHIBITOR BACKGROUND
|
| Shi Q., Fahs S.A., Wilcox D.A., Weiler H., Montgomery R.R. |
| |
|
TREATMENT OF DIC AS A COMPLICATION OF POLYTRANSFUSION AT PATIENT WITH OBSTETRIC HEMORRHAGE-CASE REPORT
|
| S. Apostolovska ., Kostovska S., Dejanova V., Neceva V., Zaturovska V. |
| |
|
TREATMENT OF GASTROINTESTINAL BLEEDING AND ANGIODYSPLASIA IN GLANZMANN THROMBASTHENIA WITH OCTREOTIDE
|
| Faurie-Bonnafous C., Clayessens S., Viallard J., Laharie D., Nurden A.T., Nurden P., Sié P. |
| |
|
TREATMENT OF IDIOPATHIC THROMBOTIC THROMBOCYTOPENIC PURPURA WITH MABTHERA (RITUXIMAB)
|
| Scully M., Liesner R., Cavenagh J., Hunt B., Benjamin S., Cohen H., Machin S.J. |
| |
|
TREATMENT OF LIFE THREATENING BLEEDING
|
| Spahn D.R. |
| |
|
TREATMENT OF PROXIMAL DEEP VEIN THROMBOSIS (DVT): RIVAROXABAN ONCE OR TWICE DAILY HAD SIMILAR EFFICACY AND SAFETY TO STANDARD THERAPY IN PHASE II STUDIES
|
| Büller H.R., Agnelli G. |
| |
|
TREATMENT OF SURGICAL PATIENTS WITH FRESH FROZEN PLASMA AT THE CLINICAL HOSPITAL CENTER RIJEKA
|
| Vukelic Damijani N., Balen S., Caser L. |
| |
|
TREATMENT OF VTE DURING PREGANCY WITH A ONCE-DAILY REGIMEN OF LMWH
|
| Parent F., Jaïs X., Wolf M., Boyer-Neuman C., Simonneau G. |
| |
|
TREATMENT WITH RECOMBINANT ACTIVATED FVII DECREASES FVIII INHIBITOR TITLE
|
| Cermelj M., Ouviña S., Guzman A., Torres O., Pollola J., Ferro A.M. |
| |
|
TRENDS IN FVIII AND FIX USE IN THE UNITED KINGDOM 2001-2006
|
| Dolan G., Hirsch S., Hollingsworth R., Rowaichi A., Dewhurst L., Hay C.R.M. |
| |
|
TRENDS IN INCIDENCE OF HEPATITIS B AND C IN FARS BLOOD DONORS FROM 2002 TILL END 2006
|
| Kasraian L. |
| |
|
TRENDS IN THE DIAGNOSTIC WORK-UP OF DEEP VENOUS THROMBOSIS OF THE LEG BETWEEN 1999 AND 2004
|
| Pomp E.R., van Stralen K.J., Bezemer I.D., Doggen C.J.M., Büller H.R., Rosendaal F.R. |
| |
|
TRITON X-100 IS RESPONSIBLE FOR THE LOSS OF ALPHA2-ANTIPLASMIN INHIBITORY ACTIVITY IN SOLVENT-DETERGENT TREATED PLASMA
|
| Burnouf T., Goubran H.A., Radosevich M., Sayed M., Gorgy G., El-Ekiaby M. |
| |
|
TRYPSIN MEDIATED ACTIVATION OF THROMBIN ACTIVATABLE FIBRINOLYTIC INHIBITOR (CARBOXYPEPTIDASE U)
|
| Kujawski M., Jeske W.P., Cunanan J., Maddineni J., Hoppensteadt D., Bick R., Fareed J. |
| |
|
TUMOR-DERIVED CYR61 PROMOTES STROMAL MATRIX METALLOPROTEINASE PRODUCTION AND ANGIOGENESIS
|
| Covic L., Kuliopulos A. |
| |
|
TWO APPARENT MISSENSE MUTATIONS IN EXONS OF THE FACTOR XI GENE CAUSE SPLICING DEFECTS DISPLAYING A NOVEL MECHANISM FOR MUTATIONS IN CLOTTING FACTORS
|
| Zucker M., Zivelin A., Bauduer F., Green D., Rosenberg N., Seligsohn U. |
| |
|
TWO NOVEL MISSENSE MUTATIONS (THR233MET AND TRP308LEU) IN THE FACTOR X GENE AND THEIR FUNCTIONAL CONSEQUENCES IN A PATIENT WITH SEVERE FACTOR X DEFICIENCY
|
| Bereczky Z., Szabó T., Haramura G., Komáromi I., Muszbek L. |
| |
|
TWO NOVEL MONOCLONAL ANTIBODIES TO VWFA3 INHIBIT VWF-COLLAGEN AND VWFPLATELET GPIB INTERACTIONS
|
| Zhao Y., Dong N., Shen F., Xie L., Ruan C. |
| |
|
TWO NOVEL MUTATIONS AND FOUR NOVEL POLYMORPHISMS IN THE FACTOR VII GENE
|
| Mathijssen N.C.J., Den Heijer M., Van Hoogen P.C.M., Schoormans S.C.M., Van Kraaij M.G.J., Nováková I.R.O., Van Heerde W.L. |
| |
|
TWO PATIENTS WITH TYPE III PROTEIN S DEFICIENCY WHO UNDERWENT CARDIAC SURGERY WITH CARDIOPULMONARY BYPASS
|
| Davidson S.J., Pepper J.F., Alexander D. |
| |
|
TYPE 1 VON WILLEBRAND DISEASE (VWD)
|
| Peake I., Goodeve A. |
| |
|
TYPE 2B VON WILLEBRAND'S DISEASE. REPORT FROM A SINGLE CENTER IN ARGENTINA
|
| Frontroth J.P., Hepner M.D., Pieroni G., Sciuccati G.B., Feliú Torres A., Bonduel M.M. |
| |
|
TYPE III COLLAGEN BINDING PROTEIN (TIIICBP) IS IDENTICAL TO KINDLIN-3, A PROTEIN BELONGING TO A NOVEL FAMILY OF FOCAL ADHESION PROTEINS
|
| Maurice P., Labas V., Vinh J., Djaafri I., Fauvel-Lafève F. |
| |
|
TYROSINE KINASE SYK PLAYS A PIVOTAL ROLE IN PLATELET SIGNALING INITIATED BY PATHOPHYSIOLOGICAL SHEAR STRESS
|
| Speich H.E., Grgurevich S., Kueter T.J., Slack S.M., Jennings L.K. |
| |
